Methods and compositions for inhibiting adam 9 biological activities
Modified ADAM9 prodomain peptides with specific amino acid substitutions and pegylation address the instability and non-specificity of existing inhibitors, achieving enhanced stability and efficacy in inhibiting ADAM9 activity for treating conditions like cancer and COPD.
Patent Information
- Application Number
- JP2024037633
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-01-31
- Filing Date
- 2024-02-19
- Publication Date
- 2024-12-06
AI Technical Summary
Existing low molecular weight inhibitors for ADAM9 activity are non-specific, leading to undesired side effects and hindering drug development due to poor pharmacokinetic properties of wild-type ADAM9 prodomains, particularly instability and sensitivity to furin and meprin cleavage.
Development of modified ADAM9 prodomain peptides with specific amino acid substitutions and pegylation to enhance stability, reduce sensitivity to furin and meprin cleavage, and improve pharmacokinetic properties, including cysteine modifications and terminal additions to facilitate conjugation with PEG groups.
The modified peptides demonstrate enhanced stability and specificity in inhibiting ADAM9 activity, showing improved potency and pharmacokinetic profiles, effectively reducing ADAM9-related pathologies such as cancer, COPD, and fibrosis.
Smart Images

Figure 2024170286000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 624,491, filed January 31, 2018, the disclosure of which is incorporated herein by reference in its entirety.
[0002] Technical Field The subject matter disclosed herein relates to compositions and methods related to the inhibition of ADAM9. In particular, the subject matter disclosed herein relates to modified and purified prodomains of ADAM9, mutations of prodomain polypeptides, and modifications that stabilize the prodomain for in vitro and in vivo use. The subject matter disclosed herein further relates to the use of the prodomain in cellular assays, and the use of the prodomain for the treatment of diseases such as cancer, fibrosis, and chronic obstructive pulmonary disease. [Background technology]
[0003] background ADAM9 is a member of the disintegrin and metalloproteinase (ADAM) family (Edwards et al., 2008), which includes enzymes such as TACE (ADAM17), ADAM8 and ADAM10. Overall, there are 33 ADAM family members in humans. ADAM proteins contain a prodomain that is important for proper folding and transport of the enzyme through the cell, a catalytic domain that contains a typical HEXXH motif, a disintegrin domain that is used to interact with integrins, a cysteine-rich region that is thought to be important for substrate recognition, a transmembrane domain, and a cytoplasmic tail that is involved in signaling events.
[0004] Members of the ADAM family are known to cleave type I and type II single-pass transmembrane proteins from cells to generate soluble mature proteins with various physiological roles (Edwards et al., 2008). For example, TACE is known to generate soluble epidermal growth factor (EGF) ligands, such as TGF-alpha, amphiregulin, and HB-EGF (Sahin et al., 2004). Similarly, ADAM10 activity generates soluble proteins, including but not limited to EGF ligands, EGF, HB-EGF, and betacellulin (Sahin et al., 2004), Notch, amyloid precursor protein, ephrins, cadherins, protocadherins, chemokines such as CXCL16 and CX3CL1, HER2, AXL, cMET, and the low-affinity IgE receptor, CD23 (reviewed in Pruessmeyer & Ludwig, 2009). Excessive ADAM9 activity may promote cell invasion and growth in tumor cell assays by increasing the production of soluble epidermal growth factor (EGF) ligand and MT-MMP16 (Moss et al., 2011). In addition, ADAM9 activity is involved in neovascularization events through the processing of Tie-2 and other factors, as well as VEGFR2 (Guaiqui et al., 2009; Maretzky et al., 2017), and plays a protective role in wound healing (Mauch et al., 2010), acute lung injury (Roychaudhuri et al., 2014), and COPD (Wang et al., 2018), as ADAM9 knockout mice performed better than their wild-type counterparts. In addition, inhibition of ADAM9 increases ADAM10 activity, which promotes the formation of soluble amyloid precursor protein alpha, which has been implicated in helping people with Alzheimer's disease (Moss et al., 2011). Inhibition of ADAM9 is also associated with an increase in BMP7, a decrease in fibrosis-associated TGF-beta RI and activin RI (see Table 1), and a decrease in MAC-1 and lymphotactin (see Table 1).These findings suggest that treatment of individuals with ADAM9 inhibitors may be beneficial in certain fibrotic and pro-inflammatory diseases.
[0005] Thus, the ability to specifically modulate ADAM9 activity would be useful for studying the biological function of this protein and for the treatment of disorders including, but not limited to, cancer, angiogenic diseases, Alzheimer's disease, wound healing, acute lung injury and chronic obstructive pulmonary disease (COPD).
[0006] Unfortunately, existing low molecular weight inhibitors are not specific for ADAM9 activity. For example, hydroxamates developed by GSK inhibit many ADAM members as well as other members of the matrix metalloproteinase family (Ludwig et al., 2005). Inhibitors disclosed by Incyte also inhibit MMPs and possibly other ADAM family members (Zhou et al., 2006). Such non-specific inhibition often results in unwanted side effects, in this case preventing the development of this compound into a drug (Moss & Sklair-Tavron, 2008).
[0007] ADAM family members are expressed as zymogens with a prodomain that maintains the enzyme in a latent state. For example, the prodomain of TACE is K iIt inhibits the activity of the catalytic domain at 50 nM and inhibits TACE activity in vivo (Wong et al., 2016). However, the wild-type prodomain of TACE does not have good pharmacokinetic properties. Mutant prodomains with modifications to the upstream furin site and cysteine residues stabilized the TACE prodomain for in vivo use (Wong et al., 2016). Similarly, the wild-type prodomain of ADAM10 does not have good pharmacokinetic properties, making ADAM10 difficult to use as a drug. The reason for the poor pharmacokinetics may be due to processing by furin convertase at the upstream cleavage site (amino acids 48-51 of human ADAM10). In addition, the only cysteine at position 173 may hinder the ability of the prodomain to have good pharmacokinetic properties as it can undergo oxidation to form a dimeric form of the prodomain. The ADAM9 prodomain has multiple meprin beta sites. ADAM10 has been shown to be a substrate of meprin beta ( Jefferson et al., 2013 ), and inhibition of meprin beta may have unwanted side effects ( Bergin et al., 2008 ; Deuss et al., 2008 ; Banerjee et al., 2011 ; Vazeille et al., 2011 ; Schette et al., 2014 ).
[0008] Unlike ADAM10 and ADAM17, the prodomain of ADAM9 contains three cysteines and an upstream furin site. These features of the prodomain make it unstable for in vitro and in vivo use. Summary of the Invention
[0009] Thus, there is a need in the art for selective inhibitors of ADAM9 to study the biological functions of ADAM9 and to treat diseases and disorders such as, but not limited to, cancer, neovascular disease, wound healing, acute lung injury, and COPD.
[0010] overview This summary lists multiple embodiments of the subject matter disclosed herein, and in many cases lists variations and permutations of these embodiments. This summary is merely illustrative of numerous embodiments and modified embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an embodiment may exist with or without the mentioned feature(s), and likewise, those features may be applied to other embodiments of the subject matter disclosed herein, whether or not they are listed in this summary. To avoid excessive repetition, this summary does not list all possible combinations of such features.
[0011] In some embodiments, the presently disclosed subject matter relates to a peptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:3, which comprises one or more amino acid substitutions and / or modifications (e.g., chemical modification of one or more sulfhydryl groups of cysteines present in SEQ ID NO:2) at amino acid positions selected from the group consisting of amino acids 6, 7, 24, 26, 27, 61, 62, 85, 104, 137, 138, 146, 160, 161, 162, 163, and 164 compared to the amino acid sequence set forth in SEQ ID NO:2, such that the peptide is less inhibitory to meprin, less sensitive to furin cleavage, less susceptible to oxidation and / or disulfide bond formation, or any combination thereof, compared to a peptide without the one or more amino acid substitutions and / or modifications. In some embodiments, the peptide comprises, consists essentially of, or consists of an amino acid sequence at least 90% identical to SEQ ID NO:2. In some embodiments, the amino acid sequence of the peptide comprises, relative to SEQ ID NO:2, one or more amino acid substitutions and / or modifications selected from the group consisting of: substitution of arginine 24 with another amino acid, optionally alanine, serine, glycine, or lysine; substitution of arginine 26 with another amino acid, optionally alanine, serine, glycine, or lysine; substitution of arginine 27 with another amino acid, optionally alanine, serine, glycine, or lysine; substitution of cysteine 85 with another amino acid, optionally serine, alanine, or glycine; substitution of cysteine 104 with another amino acid, optionally serine, alanine, or glycine; substitution of cysteine 146 with another amino acid, optionally serine, alanine, or glycine, and chemical modifications of one, two, or all three of cysteines 85, 104, and 146, or any combination thereof.In some embodiments, this amino acid sequence has a substitution at one or both of amino acids 6 and 7 compared to SEQ ID NO:2, where each substitution is independently any amino acid other than the amino acid present in SEQ ID NO:2 at the corresponding position, optionally each substitution is independently selected from the group consisting of alanine, serine, and glycine, and / or at one, two, or all three of amino acids 24, 26, and 27, where each substitution is independently any amino acid other than the amino acid present in SEQ ID NO:2 at the corresponding position, optionally each substitution is independently selected from the group consisting of alanine, serine, glycine, and lysine, and / or at one or both of amino acids 61 and 62, where each substitution is independently any amino acid other than the amino acid present in SEQ ID NO:2 at the corresponding position, optionally each substitution is independently selected from the group consisting of alanine, serine, glycine, and lysine, and / or at one, two, or all three of amino acids 62 and 63, where each substitution is independently selected from the group consisting of alanine, serine, glycine, and lysine, and / or at one, two, or all three of amino acids 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 108, 109, 102, 104 and / or having a substitution at one or both of amino acids 137 and 138, each substitution being independently any amino acid other than the amino acid present in SEQ ID NO:2 at the corresponding position, optionally each substitution being independently selected from the group consisting of asparagine, alanine, serine, and glycine, and / or having a substitution at one, two, three, four, or all five of amino acids 160-164, each substitution being independently selected from the group consisting of asparagine, alanine, serine, and glycine, and / or having a substitution at one, two, three, four, or all five of amino acids 160-164, each substitution being independently selected from the group consisting of asparagine, alanine, serine, and glycine, any amino acid other than that amino acid present in NO:2, optionally with each substitution independently selected from the group consisting of alanine, serine, glycine, and asparagine, and / or having substitutions at one, two or all three of amino acids 85, 104 and 146, each substitution independently being any amino acid other than cysteine, optionally with each substitution independently selected from the group consisting of serine, alanine and glycine, or any combination or subcombination of the above.In some embodiments, the amino acid sequence has, relative to SEQ ID NO:2, a serine at amino acid 85 and a serine at amino acid 104; an alanine at amino acid 26 and a serine at amino acids 85, 104, and 146; an alanine at amino acid 24 and a serine at amino acids 85, 104, and 146; an alanine at amino acid 27 and a serine at amino acids 85, 104, and 146; an alanine at amino acid 26; a serine at amino acids 85, 104, and 146; and an alanine at amino acid 62; a glycine at amino acid 27 and a serine at amino acids 85, 104, and 146; a serine at amino acid 27 and a serine at amino acids 85, 104, and 146; an alanine at amino acid 27; a serine at amino acids 85, 104, and 146; an alanine at amino acid 27; a serine at amino acids 85, 104, and 146; and an alanine at amino acid 62; deletion of amino acids 1-6 of SEQ ID NO:3; an alanine at amino acid 27 and a serine at amino acids 85, 104, and 146; and a serine at amino acid 138; an alanine at amino acid 27 and a serine at amino acids 85, 104, and 146 and an asparagine at amino acids 161 and 163; an addition of alanine at amino acid 26 and a serine at amino acids 85, 104, and 146 and a pentapeptide C-terminal to amino acid 174 of SEQ ID NO:3, alanine at amino acid 27 and a serine at amino acids 85, 104, and 146; an addition of alanine at amino acid 27 and a serine at amino acids 85, 104, and 146 and a GSCGS (SEQ ID NO:26) pentapeptide N-terminal to amino acid 1 of SEQ ID NO:3; and an alanine at amino acid 27 and a serine at amino acids 85, 104, and 146 and a GSGSC (SEQ ID NO:26) pentapeptide N-terminal to amino acid 1 of SEQ ID NO:3, ID NO:27) has a pentapeptide C-terminal addition. In some embodiments, one, two or all three of cysteines 85, 104, and 146 are chemically modified with a sulfhydryl group, and optionally the sulfhydryl group(s) are chemically modified by addition of a maleimide ester, an α-halocarbonyl, a thiosulfonate, or any combination thereof.In some embodiments, the amino acid sequence comprises, consists essentially of, or consists of one or more substitutions of arginines 24, 26 and / or 27 with an amino acid other than arginine, one or more substitutions of cysteines 85, 104 and 146 with an amino acid other than cysteine, optionally with a serine, or any combination thereof.
[0012] In some embodiments, the peptides of the presently disclosed subject matter further comprise a pegylated cysteine attached to the N-terminus, C-terminus, or both, optionally with one or both of the pegylated cysteines comprising a PEG group having a molecular weight of about 1 kilodalton (kDa) to about 40 kDa. In some embodiments, the amino acid sequence comprises, consists essentially of, or consists of substitution of at least one of arginine 24, arginine 26, and arginine 27 with an amino acid other than arginine, and substitution of cysteines 85, 104, and 146 with serine. In some embodiments, the amino acid at position 146 is a cysteine, and further, cysteine 146 is pegylated, optionally with cysteine 146 comprising a PEG group having a molecular weight of about 1 kDa to about 40 kDa. In some embodiments, one or more of cysteines 85, 104, and 146 comprise a chemical modification with a maleimide ester.
[0013] In some embodiments, the peptides of the presently disclosed subject matter further comprise modifications of arginine 24, arginine 26 and / or arginine 27 to increase the resistance of the peptide to furin cleavage. In some embodiments, the modifications of arginine 24, arginine 26 and / or arginine 27 are independently selected from the group consisting of substitution and chemical modification at each amino acid with any amino acid other than cysteine, in some embodiments, a chemical modification that modifies the sulfhydryl group of a cysteine to a group that is less resistant to oxidation. In some embodiments, one or more of cysteines 85, 104 and 146 comprise a chemical modification obtained by reacting the one or more cysteines with a disulfide.
[0014] In some embodiments, a peptide of the presently disclosed subject matter comprises, consists essentially of, or consists of an amino acid sequence having at least 87% percent identity to any one of SEQ ID NOs: 3-23 and 28-430, 947, optionally the percent identity is at least 93%, and even optionally the percent identity is at least 95%. In some embodiments, the peptide comprises, consists essentially of, or consists of an amino acid sequence having 100% percent identity over its entire length to any one of SEQ ID NOs: 3-23 and 28-430, 947.
[0015] In some embodiments, the peptides of the presently disclosed subject matter further comprise one or more additional modifications selected from the group consisting of conservative amino acid substitutions, unnatural amino acid substitutions, D- or D,L-racemic mixture isomeric amino acid substitutions, amino acid chemical substitutions, carboxy- and / or amino-terminal modifications, glycosylation, and conjugation to biocompatible molecules such as, but not limited to, fatty acids and other peptides of interest.
[0016] In some embodiments, the peptides of the presently disclosed subject matter further comprise a modification of at least one of cysteines 85, 104 and / or 146, wherein the modification comprises attachment of a maleimide ester derivative comprising at least one moiety selected from the group consisting of a PEG group, a fluorescent moiety, an alkyl moiety, a colorimetric moiety, a bifunctional moiety, a radiometric moiety, a glycosyl moiety, a fatty acid moiety, a toxin, a therapeutic agent, optionally a chemotherapeutic agent, a linker, a peptide of interest, or any combination thereof.
[0017] In some embodiments, the subject matter disclosed herein also relates to a composition comprising the peptides disclosed herein. In some embodiments, the composition is formulated for administration to a subject or is a pharmaceutical composition formulated for administration to a human.
[0018] In some embodiments, the subject matter disclosed herein also relates to a fusion protein comprising the peptide disclosed herein.In some embodiments, the fusion protein comprises a peptide conjugated to an agent selected from the group consisting of a therapeutic moiety, a diagnostic moiety, a detectable moiety, or any combination thereof, and optionally the peptide is conjugated to the agent via a linker molecule or via a peptide bond.In some embodiments, the therapeutic molecule is selected from the group consisting of a therapeutic antibody, an Fc fragment, a receptor, a toxin, a chemotherapeutic molecule, or any combination thereof.
[0019] In some embodiments, the presently disclosed subject matter also relates to a polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence set forth in any of SEQ ID NOs:3-23 and 28-430, 947. In some embodiments, the polypeptide does not comprise SEQ ID NO:2, i.e., the amino acid sequence contains at least one substitution, chemical modification, or any combination thereof, compared to SEQ ID NO:2.
[0020] In some embodiments, the polypeptides of the presently disclosed subject matter further comprise a tag, optionally a His tag, that can be used to purify and / or isolate the polypeptide from an expression system.
[0021] In some embodiments, the polypeptides of the presently disclosed subject matter further comprise a recognition site for a protease between the tag and an amino acid of the polypeptide that can be used to release the tag from the polypeptide by proteolytic cleavage.
[0022] In some embodiments, the presently disclosed subject matter also relates to a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs:3-23 and 28-430,947, further comprising the addition of one or more amino acids to the N-terminus of the polypeptide, the addition of one or more amino acids to the C-terminus of the polypeptide, or the addition of one or more amino acids to both the N-terminus and C-terminus of the polypeptide, wherein the one or more amino acids comprise at least one cysteine residue that provides functionality for conjugating a moiety to the polypeptide. In some embodiments, the one or more amino acids added to the N-terminus of the polypeptide comprise, consist essentially of, or consist of SEQ ID NO:26 and / or the one or more amino acids added to the C-terminus of the polypeptide comprise, consist essentially of, or consist of SEQ ID NO:27. In some embodiments, the polypeptide further comprises a PEG group conjugated to a cysteine present in one or more amino acids added to the N-terminus and / or C-terminus of the polypeptide, which PEG group enhances proper folding of the polypeptide and / or stabilizes the polypeptide against meprin cleavage compared to a polypeptide lacking the PEG group.
[0023] In some embodiments, the subject matter disclosed herein also relates to a method for modulating ADAM9 biological activity in vitro. In some embodiments, the method comprises contacting a solution or cell containing an ADAM9 protein with a peptide or composition disclosed herein in an amount sufficient to inhibit the activity of the ADAM9 protein.
[0024] In some embodiments, the subject matter disclosed herein also relates to a method for inhibiting ADAM9 biological activity in a subject. In some embodiments, the method comprises administering to a subject a peptide or composition disclosed herein in an amount and by a route sufficient to contact an ADAM9 polypeptide present in the subject, thereby modulating ADAM9 biological activity in the subject.
[0025] In some embodiments, the subject matter disclosed herein also relates to a method for inhibiting ADAM9 biological activity in vivo. In some embodiments, the method comprises administering to a subject a polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 3-23 and 28-430, 947, in an amount and by a route sufficient to inhibit ADAM9 biological activity in vivo, and optionally, the polypeptide is pegylated.
[0026] In some embodiments, the subject matter disclosed herein also relates to a method for inhibiting ADAM9 biological activity associated with a disease or disorder in a subject. In some embodiments, the method comprises contacting an ADAM9 protein present in the subject with an effective amount of a peptide or composition disclosed herein, wherein the disease or disorder is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, wounds and undesired angiogenesis, or the subject is predisposed thereto. In some embodiments, the disease or disorder comprises lung injury, optionally lung injury caused by exposure to cigarette smoke, and the effective amount is sufficient to reduce elastin degradation, inflammation, matrix metalloprotein biological activity, or any combination thereof, in one or both of the subject's lungs. In some embodiments, the disease or disorder comprises lung injury, optionally liver injury associated with liver fibrosis, and the effective amount is sufficient to reduce biological activity of MMP9 gene product, ADAM8 gene product, or any combination thereof, in the liver of the subject. In some embodiments, the disease or disorder results at least in part from excessive cell proliferation associated with ADAM9 biological activity. In some embodiments, the subject has a disease or disorder characterized, at least in part, by undesirably high ADAM9 biological activity or ADAM9 protein expression. In some embodiments, the subject has a disease or disorder characterized, at least in part, by reduced ADAM10 activity.
[0027] In some embodiments, the subject matter disclosed herein also relates to a method for reducing inflammation, hi some embodiments, the method comprises administering to a subject an effective amount of a peptide or composition disclosed herein.
[0028] In some embodiments, the subject matter disclosed herein also relates to a method for inhibiting cell infiltration associated with undesired ADAM9 biological activity in a subject. In some embodiments, the method comprises administering to a subject in need thereof an effective amount of a peptide or composition disclosed herein.
[0029] In some embodiments, the presently disclosed subject matter also relates to a method for inhibiting release of an ADAM9 substrate in vivo, hi some embodiments, the method comprises administering to a subject in need thereof a peptide comprising, consisting essentially of, or comprising an amino acid sequence set forth in any one of SEQ ID NOs: 3-23 and 28-430, 947, optionally wherein the peptide is pegylated.
[0030] In some embodiments of the methods disclosed herein, the peptide or composition is formulated for administration via a route selected from the group consisting of inhalation, oral administration, intraadipose administration, intra-arterial administration, intra-articular administration, intracranial administration, intradermal administration, intralesional administration, intramuscular administration, intranasal administration, intraocular administration, intrapericardial administration, intraperitoneal administration, intrapleural administration, intraprostatic administration, intrarectal administration, intrathecal administration, intratracheal administration, intratumoral administration, intraumbilical administration, intravaginal administration, intravenous administration, intravesical administration, intravitreal administration, subconjunctival administration, subcutaneous administration, sublingual administration, topical administration, transbuccal administration, oropharyngeal aspiration, and transdermal administration. In some embodiments, the peptide or composition is delivered in a lipid composition, optionally in a liposome or ethosome; in a cream; via a catheter; by lavage; via infusion, optionally via continuous infusion; via inhalation; via injection; via topical delivery; via localized perfusion; by directly bathing the target cells; or any combination thereof.
[0031] In some embodiments, the presently disclosed subject matter also relates to methods for attaching a peptide consisting of, consisting essentially of, or including an amino acid sequence set forth in any of SEQ ID NOs:3-23 and 28-430, 947 to an antibody, antibody fragment, or other protein, the method comprising conjugating the peptide to the antibody, antibody fragment, or other protein, optionally via a linker, and further optionally via a peptide linker.
[0032] In some embodiments, the subject matter disclosed herein also relates to the use of an antibody, an antibody fragment, a polypeptide, a protein, a specific antibody, a monoclonal antibody, a peptide, an inhibitory nucleic acid, and / or a low molecular weight inhibitor of ADAM9 biological activity for preventing the onset of at least one symptom of a disorder associated with undesired ADAM9 biological activity in a subject in need thereof and / or reducing the severity of the symptom, and optionally the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, and undesired angiogenesis.In some embodiments, the subject is a human.In some embodiments, the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of COPD and fibrosis, and optionally the fibrosis is liver fibrosis.
[0033] In some embodiments, the presently disclosed subject matter also relates to a peptide comprising, consisting essentially of, or consisting of any of SEQ ID NOs:3-23 and 28-430, 947, wherein at least one meprin cleavage site present therein has been modified to render the peptide less inhibitory to meprin, and optionally the at least one meprin cleavage site is selected from the group consisting of amino acids 5-7 of SEQ ID NO:3, amino acids 60-62 of SEQ ID NO:3, amino acids 136-138 of SEQ ID NO:3, and amino acids 159-164 of SEQ ID NO:3, and further wherein the at least one meprin cleavage site is selected from the group consisting of amino acids 5-7 of SEQ ID NO:3, amino acids 60-62 of SEQ ID NO:3, amino acids 136-138 of SEQ ID NO:3, and amino acids 159-164 of SEQ ID NO:3. and wherein at least one meprin cleavage site present therein is modified to contain an amino acid sequence selected from the group consisting of FXX, PXX, MXX, FXQ, FQX, PXD, PEX, MXD, MDX, KXEXEX, KDXEXE, KDXXXE, KXEXXE, KXXEXE, KDXXXX, KXEXXX, KXXEXX, KXXXEX, KXXXXE, KXXXXX, or any combination thereof, wherein each X is independently any amino acid sequence, and further optionally each X is independently selected from the group consisting of asparagine, glycine, alanine, and serine.
[0034] In some embodiments, the subject matter disclosed herein also relates to a polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence set forth in any one of SEQ ID NOs:3-23 and 28-430, 947, wherein one or more cysteines corresponding to amino acid residues of SEQ ID NO:3 selected from the group consisting of cysteines 85, 104 and 146, or any combination thereof, are conjugated to one or more moieties that improve the inhibitory potency, solubility, and / or pharmacokinetic properties of the polypeptide compared to a polypeptide lacking the moiety, and / or are conjugated to one or more chromophores, fluorophores, and / or radionuclides.
[0035] In some embodiments, the subject matter disclosed herein also relates to a polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence set forth in one of SEQ ID NOs:3-23 and 28-430,947 for use in treating a subject having a disorder associated with undesired ADAM9 biological activity, optionally wherein the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, wounds, and undesired angiogenesis, and optionally wherein the polypeptide is pegylated at one or more of the amino acids of SEQ ID NOs:3-23 and 28-430,947. In some embodiments, the polypeptide is pegylated. In some embodiments, the subject is a human.
[0036] In some embodiments, the subject matter disclosed herein also relates to the use of the inhibitor of ADAM9 biological activity for treating a subject with a disorder associated with undesired ADAM9 biological activity.In some embodiments, the inhibitor of ADAM9 biological activity is selected from the group consisting of an antibody or a fragment thereof, and optionally the antibody is a monoclonal antibody, a protein, a peptide, an inhibitory nucleic acid, and / or a low molecular weight substance, and optionally the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, wounds, and undesired angiogenesis.In some embodiments, the subject is a human.
[0037] In some embodiments, the subject matter disclosed herein also relates to a polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence set forth in one of SEQ ID NOs: 3-23 and 28-430,947 for use in preventing the onset and / or reducing the severity of at least one symptom of a disorder associated with undesired ADAM9 biological activity. In some embodiments, the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, wounds, and undesired angiogenesis in a subject in need thereof, and optionally the subject is predisposed to developing at least one symptom. In some embodiments, the polypeptide is pegylated. In some embodiments, the subject is a human. In some embodiments, the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of COPD and fibrosis, and optionally the fibrosis is liver fibrosis.
[0038] In some embodiments, the presently disclosed subject matter also relates to a peptide comprising, consisting essentially of, or consisting of any of SEQ ID NOs:3-23 and 28-430,947, wherein at least one furin or furin-like cleavage site present therein has been modified to render the at least one furin or furin-like cleavage site more resistant to cleavage by a furin or furin-like convertase compared to the at least one furin or furin-like cleavage site that is not modified. In some embodiments, the at least one furin or furin-like cleavage site consists of the tetrapeptide sequence RXRR, RXKR, RXXR, or RXRK, where X is any amino acid.
[0039] In some embodiments, the subject matter disclosed herein also relates to a polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence set forth in any one of SEQ ID NOs:3-23 and 28-430,947, wherein the amino acid sequence comprises one or more charged amino acid substitutions compared to SEQ ID NO:2, such that the solubility of the polypeptide is increased in a given solvent compared to a polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:2, and further wherein the given solvent is selected from the group consisting of biological fluids and cell culture media.
[0040] In some embodiments, the subject matter disclosed herein also relates to a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs:3-23 and 28-430, 947, and optionally further comprising a C-terminal spacer containing one or more charged residues selected from the group consisting of Asp, Glu, Arg and Lys, wherein the solubility of the polypeptide with the C-terminal spacer in a given solvent is greater than that of the same polypeptide absent the C-terminal spacer.
[0041] In some embodiments, the subject matter disclosed herein also relates to a polypeptide comprising an amino acid sequence set forth in any one of SEQ ID NOs:3-23 and 28-430,947, and optionally further comprising an N-terminal spacer containing one or more charged residues selected from the group consisting of Asp, Glu, Arg and Lys, wherein the solubility of the polypeptide with the N-terminal spacer in a given solvent is greater than that of the same polypeptide absent the N-terminal spacer.
[0042] In some embodiments, the peptides, polypeptides, and / or fusion proteins disclosed herein of the presently disclosed subject matter are modified by amino acid substitution, chemical modification, or a combination thereof, such that the peptides, polypeptides, and / or fusion proteins are less susceptible to cleavage by meprin compared to the peptides, polypeptides, and / or fusion proteins lacking the modification(s). In some embodiments, the modification is at one or more of cysteines 85, 104, and / or 146 of SEQ ID NO:3, or at a position in the peptide, polypeptide, and / or fusion protein corresponding to one or more of cysteines 85, 104, and / or 146 of SEQ ID NO:3.
[0043] In some embodiments, the herein disclosed peptides, polypeptides, and / or fusion proteins of the presently disclosed subject matter are present in a composition, optionally a pharmaceutical composition, which is formulated for administration to a subject or is a pharmaceutical composition formulated for administration to a human.
[0044] The above-stated objects, other objects and advantages of the subject matter disclosed herein will become apparent from a review of the following detailed description and examples, particularly in light of the drawings. [Brief description of the drawings]
[0045] [Figure 1]1 shows a stained gel showing the effect of storage of wild-type ADAM9 prodomain peptide (SEQ ID NO:2) at -20°C, specifically with respect to dimer and trimer formation. Upon storage, SEQ ID NO:2 precipitated after 2 weeks. The gel shows freshly prepared SEQ ID NO:2 (left panel) and the urea-solubilized precipitate after 2 weeks of storage at -20°C (right panel). [Diagram 2] SDS PAGE gel of freshly refolded and dialyzed SEQ ID NO:2 or SEQ ID NO:10 (0.5 μg / μl) after various incubation times at 37° C. in 20 mM Tris buffer pH 8. Protein dimerization and trimerization were visualized by running SDS PAGE gels and subsequent staining with SimplyBlue (Fisher Scientific, Pittsburgh, PA). MWM indicates prestained molecular weight marker. Both peptides contain free sulfhydryl groups (SEQ ID NO:9 has a C146S mutation) and are sensitive to oxidation, and the amount of dimer and trimer formation increased over time. [Diagram 3] 1 depicts a stained gel showing efficient labeling of wild-type ADAM9 prodomain peptide (SEQ ID NO:2) with ALEXA FLUOR® 647 brand maleimide ester fluorophore. Little to no dimer or starting material was present in the modified SEQ ID NO:2, indicating that labeling was complete. In addition, the molecular weight was shifted approximately 3 kDa higher, indicating that the prodomain was successfully modified on the three cysteines (i.e., the prodomain also had no free sulfhydryl groups as determined by Ellman's reagent). [Figure 4] Figure 1 shows a stained gel showing cleavage of various modified ADAM9 prodomain peptides by furin at 0, 30 and 60 minutes. SEQ ID NO:12 was the most stable mutant. In addition, other furin mutants were also less resistant to cleavage compared to the non-furin mutant SEQ ID NO:13. [Diagram 5]1 depicts a stained gel showing cleavage of various modified ADAM9 prodomain peptides by meprin at 0 and 10 minutes. The rightmost lane is a molecular weight marker, with the positions of the bands corresponding to the 15 kDa, 25 kDa, and 35 kDa markers labeled. SEQ ID NO:12, which lacks meprin mutations, was less stable compared to all meprin mutants shown. [Figure 6] 1 depicts a stained gel showing cleavage of various modified ADAM9 prodomain peptides by meprin at 0, 10 and 40 minutes. SEQ ID NO:19 with substitutions at amino acids 161 and 163 was the most stable compared to mutations at amino acids 62 or 138. [Figure 7] 1 depicts a stained gel showing cleavage of various modified ADAM9 prodomain peptides, unpegylated or pegylated, by meprin at 0 and 10 minutes. SEQ ID NO:12 represents the non-pegylated peptide, and the "p" in front of SEQ ID NOs:21-23 indicates that these peptides are pegylated at cysteine 146 (SEQ ID NO:21), at the N-terminus (SEQ ID NO:22), and at the C-terminus (SEQ ID NO:23). [Figure 8] 1 depicts a stained gel showing cleavage of wild-type ADAM9 prodomain peptide by meprin at 0, 10, 40 and 120 minutes. The positions of the prodomain monomers and dimers are labeled. The leftmost lane is a molecular weight marker, and the positions of the bands corresponding to the 15 kDa, 25 kDa, 30 kDa and 40 kDa markers are labeled. The gel shows that the wild-type ADAM9 prodomain peptide was cleaved by meprin. [Figure 9]9A-9B. Bar graphs showing the results of experiments on the ability of human ADAM9 prodomain peptides to inhibit the shedding of various known ADAM9 substrates (MMP9, FGF-4, I309, MCP-3, MCP-4, and TGFα) in vitro as measured by fluorescence units (FU) (FIG. 9A) and to inhibit VEGFR2 activity (FIG. 9B). Furin mutants SEQ ID NO:12 and SEQ ID NO:13 (non-furin mutants) were tested at 30 nM and 300 nM. In addition, C-terminal pegylated SEQ ID NO:20 was also tested at 100 nM. For each substrate, there are six bars in Figure 9A, from left to right: an average of 3 nM pooled SEQ ID NOs:12 and 13 (representing no inhibition), 300 nM furin mutant SEQ ID NO:12, 30 nM furin mutant SEQ ID NO:12, 300 nM furin mutant SEQ ID NO:13 (no furin mutation), 30 nM SEQ ID NO:13 (no furin mutation), and 100 nM C-terminally pegylated SEQ ID NO:20 (a furin mutant that is more susceptible to cleavage than SEQ ID NO:12 but better than SEQ ID NO:13). In Figure 9B, the percent inhibition of VEGFR2 signaling compared to vehicle control is shown for 30nM and 300nM furin mutant SEQ ID NO:12, 30nM and 300nM SEQ ID NO:13 (non-furin mutant) and 100nM C-terminal pegylated SEQ ID NO:20. Error bars are + standard error of the mean (SEM). SEQ ID NO:12 reduced most of the protein levels and had a better ability than SEQ ID NO:13. Pegylated SEQ ID NO:20 also had the best IC50 using in vitro enzyme assay and appeared to be the most potent inhibitor. [Figure 10]1 is a bar graph showing the results of an experiment on the ability of human ADAM9 prodomain peptides to inhibit elastin degradation in an acute cigarette smoke (CS) model, as measured by ELISA for desmosine. Error bars are + standard error of the mean (SEM). SEQ ID NO:10 or vehicle control was given intranasally for two weeks. Elastin degradation was completely blocked by administration of SEQ ID NO:10. [Figure 11] 1 is a bar graph of serum prodomain levels measured as described 72 hours after mice were ip injected with the prodomain or vehicle control. Data represent the average of 2-3 sera. Error bars indicate SEM for each sample. peg indicates the prodomain peptide is PEGylated. N-terminally PEGylated SEQ ID NO:22 was the most stable to meprin and furin cleavage and had the highest serum levels after 72 hours. The other PEGylated prodomains had lower serum levels than non-PEGylated SEQ ID NO:12, indicating that N-terminal PEGylation was best. SEQ ID NO:14, which has a furin site that was more stable to meprin but not completely resistant to cleavage, had lower serum levels than SEQ ID NO:12 without the meprin mutation, indicating that in addition to meprin stability, furin stability enhances the pharmacokinetic properties. [Figure 12] 1 is a series of graphs showing levels of various liver enzyme function markers in an acute liver injury model in mice either treated (treated) or not (vehicle) with furin mutant SEQ ID NO:12. The top left panel shows aspartate aminotransferase (AST) levels, the top right panel shows alanine aminotransferase (ALT) levels, the bottom left panel shows bilirubin levels, the bottom center bar shows liver weight, and the bar in the bottom right panel shows liver fibrosis score measured by determining collagen deposition. Liver enzyme levels, bilirubin levels, liver weight, and fibrosis score were all reduced by SEQ ID NO:12 treatment compared to vehicle control. Error bars are + standard error of the mean (SEM). [Figure 13]FIG. 13 is a series of graphs showing enzyme concentrations of MMP9 (top left panel), MMP13 (top right panel), and ADAM8 (bottom panel) in mouse liver homogenates from the acute liver injury model previously described for FIG. 12. The data showed that SEQ ID NO:12 treatment reduced levels of MMP9 and ADAM8 in liver samples, and MMP13 levels were increased. Error bars are + standard error of the mean (SEM). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0046] REFERENCE TO A SEQUENCE LISTING SUBMITTED ON A COMPACT DISC The sequence listings relevant to this disclosure have been submitted as three 671 MB files on three compact discs (CRF Copy, Copy 1, and Copy 2, each compact disc being identical in content). The compact discs are printed in Indelible Ink to identify the applicant, title, filename (FINAL_3217_4_PCT_ST25.txt), creation date (January 31, 2019), computer system (ASCII DOS format), docket number (3217 / 4 PCT), and serial number of the corresponding U.S. utility application. The sequence listings submitted on the compact discs are incorporated by reference into this disclosure in their entirety.
[0047] Brief description of sequence listing SEQ ID NO:1 is the amino acid sequence of an exemplary human ADAM9 gene product as set forth in the GENBANK® Biosequence Database, Accession No. NP_003807.1.
[0048] SEQ ID NO:2 is the amino acid sequence of an exemplary human ADAM9 prodomain peptide, which corresponds to amino acids 30-203 of SEQ ID NO:1.
[0049] SEQ ID NO:3 is the consensus core amino acid sequence of the modified ADAM9 prodomain peptides of the presently disclosed subject matter, which is based on SEQ ID NO:2 and differs from SEQ ID NO:2 due to the positions where the modified ADAM9 prodomain peptides of the presently disclosed subject matter differ from SEQ ID NO:2 within the core represented by X, where X is any amino acid or modification thereof.
[0050] SEQ ID NO:4 is SEQ ID NO:3 with the addition of an N-terminal cysteine.
[0051] SEQ ID NO:5 is SEQ ID NO:3 with the addition of a C-terminal cysteine.
[0052] SEQ ID NO:6 is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 is substituted at amino acids 24, 26 and 27 in the furin recognition site.
[0053] SEQ ID NO:7 is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has been substituted in the furin recognition site at amino acids 24, 26 and 27, and cysteines 85 and 104 have been substituted with serine.
[0054] SEQ ID NO:8 is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has cysteines 85 and 104 substituted with serine.
[0055] SEQ ID NO:9 is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has a furin recognition site at amino acid 26 replaced with an alanine and cysteine 146 also replaced with a serine substitution.
[0056] SEQ ID NO:10 (also referred to herein as "Seq11") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has a furin recognition site at amino acid 26 replaced with an alanine, and cysteines 85, 104 and 146 are also replaced with serine substitutions.
[0057] SEQ ID NO:11 (also referred to herein as "Seq17B") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has the furin recognition site at amino acid 24 replaced with an alanine and cysteines 85, 104 and 146 replaced with serine substitutions.
[0058] SEQ ID NO:12 (also referred to herein as "Seq25") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has the furin recognition site at amino acid 27 replaced with an alanine and cysteines 85, 104 and 146 replaced with serine substitutions.
[0059] SEQ ID NO:13 (also referred to herein as "Seq26") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has been substituted at cysteines 85, 104 and 146 with serine substitutions.
[0060] SEQ ID NO:14 (also referred to herein as "Seq27") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has a furin recognition site at amino acid 26 replaced with an alanine, a second meprin recognition site at amino acid 62 replaced with an alanine, and cysteines 85, 104, and 146 replaced with serine substitutions.
[0061] SEQ ID NO:15 (also referred to herein as "Seq28") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has a furin recognition site at amino acid 27 replaced with a glycine, and also has serine substitutions at cysteines 85, 104 and 146.
[0062] SEQ ID NO:16 (also referred to herein as "Seq29") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has a furin recognition site at amino acid 27 replaced with a serine, and also has serine substitutions at cysteines 85, 104 and 146.
[0063] SEQ ID NO:17 (also referred to herein as "Seq30") is a modified ADAM9 prodomain peptide in which amino acids 1-6 of the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 have been deleted, the furin recognition site has been replaced with alanine at amino acid 27, and cysteines 85, 104, and 146 have been replaced with serine.
[0064] SEQ ID NO:18 (also referred to herein as "Seq31") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has the furin recognition site at amino acid 27 replaced with alanine, the third meprin recognition site at amino acid 138 replaced with serine, and cysteines 85, 104, and 146 replaced with serine.
[0065] SEQ ID NO:19 (also referred to herein as "Seq32") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has the furin recognition site at amino acid 27 replaced with alanine, the fourth meprin recognition site at amino acids 161 and 163 replaced with asparagine, and cysteines 85, 104 and 146 replaced with serine.
[0066] SEQ ID NO:20 (also referred to herein as "Seq11C2") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has the furin recognition site at amino acid 26 replaced with alanine, cysteines 85, 104 and 146 replaced with serine, and has a pentapeptide added to the C-terminus.
[0067] SEQ ID NO:21 (also referred to herein as "Seq25-1") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has the furin recognition site at amino acid 27 replaced with alanine and cysteines 85 and 104 replaced with serine.
[0068] SEQ ID NO:22 (also referred to herein as "Seq25-2") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has the furin recognition site at amino acid 27 replaced with alanine, cysteines 85, 104 and 146 replaced with serine, and has a pentapeptide added to the N-terminus.
[0069] SEQ ID NO:23 (also referred to herein as "Seq25-3") is a modified ADAM9 prodomain peptide in which the wild-type human ADAM9 prodomain peptide of SEQ ID NO:2 has the furin recognition site at amino acid 27 replaced with alanine, cysteines 85, 104 and 146 replaced with serine, and has a pentapeptide added to the C-terminus.
[0070] SEQ ID NO:24 is the sequence of a His tag peptide consisting of six His amino acids.
[0071] SEQ ID NO:25 is an exemplary meprin recognition sequence that corresponds to the fourth meprin recognition sequence of the ADAM9 prodomain peptide of SEQ ID NO:2.
[0072] SEQ ID NO:26 is an exemplary pentapeptide sequence that can be attached to the N-terminus of a modified ADAM9 prodomain peptide of the presently disclosed subject matter to provide functionality for conjugating a PEG group.
[0073] SEQ ID NO:27 is an exemplary pentapeptide sequence that can be attached to the C-terminus of a modified ADAM9 prodomain peptide of the presently disclosed subject matter to provide functionality for conjugating a PEG group.
[0074] SEQ ID NOs:28-430, 947 are amino acid sequences of exemplary ADAM9 prodomain peptides of the presently disclosed subject matter.
[0075] Detailed Description The subject matter disclosed herein relates, in some embodiments, to modified ADAM9 modulating peptides and related compositions that are useful for examining the biological function of ADAM9 and / or for treating diseases and disorders associated with unwanted ADAM9 biological activity, including, but not limited to, cancer, inflammation, COPD (characterized by any phenotype, such as small airway fibrosis, mucosal metaplasia and emphysema), fibrosis, Alzheimer's disease, wounds and unwanted angiogenesis, as well as disorders characterized, at least in part, by inflammation, excessive cell proliferation, angiogenesis, fibrosis, and the presence of one or more of the excess or decreased soluble proteins listed in Table 1. [Table 1]
[0076] Thus, in some embodiments, the subject matter disclosed in this specification provides specific inhibitors of ADAM9 activity and methods for using the same for studying the biological functions of ADAM9 and / or for treating diseases and disorders associated with undesirable ADAM9 biological activity.
[0077] The presently disclosed subject matter will now be described more fully in the following sections, which describe some, but not all, embodiments of the presently disclosed subject matter. Indeed, the presently disclosed subject matter may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein, but rather these embodiments are provided so that this disclosure will satisfy applicable legal requirements.
[0078] I. Definition The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the subject matter disclosed herein.
[0079] Although the following terms are believed to be well understood to those of ordinary skill in the art, the following definitions are provided to facilitate the description of the subject matter disclosed herein.
[0080] All technical and scientific terms used herein shall have the same meaning as commonly understood by those skilled in the art, unless otherwise defined below. References to technology used herein shall refer to technology commonly understood in the art, including modifications of technology commonly understood in the art that are obvious to those skilled in the art, or substitutions of equivalent technology. While the following terms are believed to be well understood by those skilled in the art, the following definitions are provided to facilitate the description of the subject matter disclosed herein.
[0081] In describing the subject matter disclosed herein, it will be understood that multiple techniques and steps are disclosed, each of which has individual benefits and each of which can also be used in conjunction with one or more, or in some instances, all, of the other disclosed techniques.
[0082] Thus, for the sake of clarity, this specification refrains from unnecessarily repeating each possible combination of the individual steps, but the specification and claims should nevertheless be read with the understanding that such combinations are within the scope of the invention and claims as a whole.
[0083] In accordance with long-standing patent law conventions, the terms "a," "an," and "the" as used herein, including the claims, refer to one or more. For example, the phrase "antibody" refers to one or more antibodies, including multiple identical antibodies. Similarly, the phrase "at least one" as used herein refers to one entity, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, or more of that entity, including, but not limited to, all numbers between 1 and 100 and greater than 100.
[0084] Unless otherwise indicated, all numerical values expressing amounts of raw materials, reaction conditions, and the like used in the specification and claims should be understood to be modified in all instances by the term "about." As used herein, the term "about," when referring to a measurable value, such as an amount of mass, weight, time, volume, concentration, or percentage value, is intended to include variations of the specified amount of ±20% in some embodiments, ±10%, ±5%, ±1%, ±0.5%, and ±0.1% in some embodiments, as such variations are appropriate for carrying out the methods of the present disclosure. Thus, unless indicated to the contrary, numerous parameters set forth in the specification and the appended claims are approximations that may vary depending on the desired properties sought to be obtained by the subject matter of the present disclosure.
[0085] As used herein, the term "and / or," when used in connection with a list of items, refers to the items present singly or in combination. Thus, for example, the phrase "A, B, C, and / or D" includes A, B, C, and D individually, but also all combinations and subcombinations of A, B, C, and D.
[0086] The term "comprising," which is synonymous with "comprising," "containing," or "characterized by," is inclusive or open-ended and does not exclude additional, unrecited elements and / or method steps. "Comprising" is a term of the art that means that the recited elements and / or steps are present, but that other elements and / or steps may be added and still be included within the scope of the relevant subject matter.
[0087] As used herein, the phrase "consisting of" excludes any element, step, or ingredient not specifically recited. Note that when the phrase "consisting of" appears in a clause in the body of a claim rather than immediately following the preamble, it limits only the elements set forth in the clause and does not exclude other elements from the claim as a whole.
[0088] The phrase "consisting essentially of" as used herein limits the scope of the relevant disclosure or claim to the specified materials and / or steps, plus those that do not materially affect the basic and novel characteristic(s) of the disclosed and / or claimed subject matter. For example, a pharmaceutical composition can "consist essentially of" one or more pharmacoactive agents, meaning that the recited pharmacoactive agent(s) are the only pharmacoactive agent(s) present in the pharmaceutical composition. However, it should be noted that carriers, excipients, and other inactive agents can and likely will be present in the pharmaceutical composition as well.
[0089] With respect to the terms "comprising," "consisting," and "consisting essentially of," when one of these three terms is used herein, the subject matter disclosed and claimed herein may encompass the use of one of the other two terms. For example, in some embodiments, the subject matter disclosed herein relates to compositions comprising an antibody. Thus, it will be understood by one of skill in the art after reviewing this disclosure that the subject matter disclosed herein encompasses compositions consisting of an antibody of the subject matter disclosed herein, as well as compositions consisting essentially of an antibody of the subject matter disclosed herein.
[0090] As used herein, the phrase "chronic obstructive pulmonary disease (COPD)" refers to chronic obstructive pulmonary disease and its significant COPD-like phenotypes, including, but not limited to, emphysema, small airway fibrosis, and mucous cell metaplasia (as they occur in the large airways of COPD patients and contribute to the chronic bronchitis phenotype).
[0091] The term "subject" as used herein refers to any member of an invertebrate or vertebrate animal species. Thus, the term "subject" is intended to include any member of the Animalia kingdom, including, but not limited to, members of the phylum Chordata (e.g., members of the classes Osteichthyes (bony fish), Amphibia (amphibians), Reptilia (reptiles), Aves (birds), and Mammalia (mammals), as well as all orders and families contained therein.
[0092] The compositions and methods of the subject matter disclosed herein are particularly useful for warm-blooded vertebrates.Thus, the subject matter disclosed herein relates to mammals and birds.More specifically, provided are compositions and methods derived from and / or for use in mammals such as humans and other primates, as well as those mammals that have endangered importance (such as Siberian tigers), economic importance (animals raised on farms for human consumption) and / or social importance to humans (animals kept as pets or in zoos), such as non-human carnivores (such as cats and dogs), swine (pigs, castrated and uncastrated boars), ruminants (such as cattle, steers, sheep, giraffes, deer, goats, oxen, and camels), rodents (such as mice, rats, and rabbits), marsupials, and horses. Also provided is the use of the disclosed methods and compositions in birds, including larger birds, more specifically domestic birds, such as poultry, for example, turkeys, chickens, ducks, geese, guinea fowl, etc., in addition to those species of birds that are endangered and kept in zoos, because they are also economically important to humans. Accordingly, also provided is the use of the disclosed methods and compositions in livestock, including, but not limited to, domestic pigs (pigs and castrated boars), ruminants, horses, poultry, etc.
[0093] Similarly, all genes, gene names and gene products disclosed herein are intended to correspond to homologs from any species to which the compositions and methods disclosed herein are applicable. Thus, the term includes, but is not limited to, genes and gene products from humans and mice. Where genes or gene products from a particular species are disclosed, it should be understood that this disclosure is illustrative only and should not be construed as limiting unless the context clearly indicates otherwise. Thus, for example, in the case of genes depicted herein, the disclosed human amino acid sequences are intended to include homologous genes and gene products from other animals, including, but not limited to, other mammals, fish, amphibians, reptiles and birds. Also included are any nucleotide sequences that encode the disclosed amino acid sequences, including, but not limited to, those disclosed in the corresponding GENBANK® entries.
[0094] Table 2 provides GENBANK® Biosequence Database accession numbers for exemplary ADAM9 nucleic acids and polypeptides of the presently disclosed subject matter. Note that the entries in Table 2 are merely exemplary. [Table 2]
[0095] It should be noted that the GENBANK® Biosequencing Database Accession Numbers provided in Table 2 represent the sequence of the full-length ADAM9 gene product, of which the prodomain peptide is only a partial sequence. For example, the human ADAM9 polypeptide sequence shown in GENBANK® Biosequencing Database Accession Number NP_003807.1 corresponds to the full-length ADAM9 precursor protein of 819 amino acids and is designated as SEQ ID NO:1. Meanwhile, the human ADAM9 prodomain peptide corresponds to amino acids 30-203 of SEQ ID NO:1 and is itself designated as SEQ ID NO:2.
[0096] The terms "cancer" and "tumor" are used interchangeably herein and may refer to both primary and metastatic solid tumors and carcinomas of any tissue in a subject, including, but not limited to, breast; colon; rectum; lung; oropharynx; hypopharynx; esophagus; stomach; pancreas; liver; gallbladder; bile duct; small intestine; urinary tract, including kidney, bladder and urothelium; female reproductive tract, including cervix, uterus and ovaries (e.g., choriocarcinoma and gestational trophoblastic disease); male reproductive tract, including prostate, seminal vesicles, testes and germ cell tumors; endocrine glands, including thyroid, adrenal glands and pituitary; skin (e.g., hemangioma and melanoma), bone or soft tissue; blood vessels (e.g., Kaposi's sarcoma); brain, nerve, eye and meninges (e.g., astrocytoma, glioma, glioblastoma, retinoblastoma, neuroma, neuroblastoma, neurinoma and meningioma). As used herein, "cancer" and "tumor" are also intended to refer to individual neoplastic or pre-neoplastic cells in addition to multicellular tumors. In some embodiments, the cancer or tumor includes a cancer or tumor of epithelial tissue, such as, but not limited to, a carcinoma. In some embodiments, the tumor is an adenocarcinoma, in some embodiments, of the pancreas, breast, ovary, colon or rectum, and / or metastatic cells derived therefrom.
[0097] The term "wound" as used herein refers to many types of wounds including, but not limited to, abrasions, lacerations, contusions, burns, penetrating wounds, puncture wounds, skin incisions, surgical wounds, pressure sores (including, but not limited to, bedsores and decubitus ulcers), diabetic wounds and ulcers, fibrotic wounds, gunshot wounds (wounds resulting from firearms), thermal wounds (burns, sunburn and frostbite), chemical wounds, bites, and stab wounds, and electrical wounds.
[0098] II. Modified ADAM9 Prodomain Peptides The presently disclosed subject matter provides, in some embodiments, modified ADAM9 prodomain peptides that have desirable biological activity relative to their unmodified counterparts. By way of example and not limitation, the modified ADAM9 prodomain peptides of the presently disclosed subject matter may, in some embodiments, be somewhat susceptible to cleavage by furin and furin-like proteins, in some embodiments, be somewhat susceptible to cleavage by meprin and meprin-like proteins, and in some embodiments, be somewhat capable of forming dimers and other multimers via cysteine bridges to themselves or to other members of the ADAM family of proteins, including but not limited to ADAM9.
[0099] As used herein, the terms "modified ADAM9 prodomain peptide," "modified ADAM9 peptide," "ADAM9 modulating peptide," and the like refer to a peptide having one or more modifications of the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:3 and / or other modifications that confer some desired biological or biochemical property of the modified ADAM9 peptide compared to the ADAM9 peptide without the modification(s), including, but not limited to, the wild-type ADAM9 prodomain peptide on which it is based. By way of example and not limitation, the types of modifications that can be introduced into the modified ADAM9 peptides of the subject matter disclosed herein include amino acid substitutions, deletions, additions and other types of modifications designed to alter one or more biological or biochemical properties of the modified ADAM9 peptide, such as, but not limited to, solubility in a given solvent (including, but not limited to, biological fluids such as blood, serum, cerebrospinal fluid, etc.), dissociation constant for a binding partner, 50% inhibitory concentration (IC50) for an enzyme (such as, but not limited to, the ADAM9 or other members of the ADAM family of disintegrins and metalloproteinases), and / or to improve various applicable pharmacokinetic properties.
[0100] With regard to the modifications encompassed by the subject matter disclosed herein, there are at least three biologically relevant features of members of the ADAM family, such as ADAM9, that can be exploited to generate modified ADAM9 peptides of the subject matter disclosed herein.By way of example and not limitation, ADAM9 protein and the prodomain peptides derived therefrom are characterized by a recognition site for furin and furin-like endoproteases, a recognition site for meprin and meprin-like metallopeptidases, and a number of cysteine residues that can form homodimers, heterodimers, and higher order multimers through the formation of disulfide bonds.In addition to cleavage by furin and furin-like endoproteases, and meprin and meprin-like metallopeptidases, the formation of disulfide bonds is related to some of the biological activities of members of the ADAM family, such as ADAM9, and the amino acid sequences that are responsible for these activities can be modified to modulate the biological activities of members of the ADAM family, such as ADAM9.
[0101] For example, the wild-type human ADAM9 prodomain peptide represented by SEQ ID NO:2 has a furin recognition site at amino acids 24-27 of SEQ ID NO:2. As disclosed herein, modification of amino acids 24, 26 and / or 27 of SEQ ID NO:2 results in modified ADAM9 peptides that have greater or lesser sensitivity to cleavage by furin and furin-like endoproteases. Similarly, the wild-type human ADAM9 prodomain peptide represented by SEQ ID NO:2 has four meprin recognition sites: amino acids 5-7 of SEQ ID NO:2 (referred to herein as the "first meprin site"); amino acids 60-62 of SEQ ID NO:2 (referred to herein as the "second meprin site"); amino acids 136-138 of SEQ ID NO:2 (referred to herein as the "third meprin site"); and amino acids 159-164 (referred to herein as the "fourth meprin site"). As disclosed herein, modification of any one of amino acids 6 and / or 7 of the first meprin site of SEQ ID NO:2, and / or amino acids 61 and / or 62 of the second meprin site of SEQ ID NO:2, and / or amino acids 137 and / or 138 of the third meprin site of SEQ ID NO:2, and / or amino acids 160-164 of the fourth meprin site of SEQ ID NO:2, or any combination thereof, results in modified ADAM9 peptides that have greater or lesser sensitivity to inhibition and / or cleavage by meprins and meprin-like metallopeptidases. Similarly, modification of any of the cysteines of SEQ ID NO:2 that are involved in disulfide bond formation, including but not limited to cysteines 85, 104, and 146 of SEQ ID NO:2, results in modified ADAM9 peptides that have greater or lesser ability to form disulfide bonds with the ADAM9 protein and / or other ADAM family member proteins. As will be appreciated by those of skill in the art, combinations of furin site modifications, meprin site modifications, and / or cysteines can result in modified ADAM9 peptides with multiple new functionalities, if desired.
[0102] Thus, in some embodiments, the ADAM9 modulating peptides of the presently disclosed subject matter having an amino acid sequence derived from SEQ ID NO:2 include at least one amino acid substitution or other modification of at least one of amino acids 24, 26 and / or 27 of SEQ ID NO:2 (i.e., the furin recognition sequence), at least one of amino acids 6, 7, 61, 62, 137, 138 and 160-164 of SEQ ID NO:2 (i.e., the meprin recognition sequence), and / or at least one of cysteines 85, 104 and 146 of SEQ ID NO:2. It will be understood that modifications, including but not limited to amino acid substitutions, can occur at any one or more of amino acids 6, 7, 24, 26, 27, 61, 62, 85, 104, 137, 138, 146, and 160-164 of SEQ ID NO:2, in any combination, and that all combinations and subcombinations of amino acid substitutions at any combination or subcombination of these amino acid positions are encompassed by the subject matter disclosed herein.
[0103] More specifically, the first meprin site of the ADAM9 prodomain is amino acids 5-7 of SEQ ID NO:2, with amino acid 6 and / or amino acid 7 substituted. In some embodiments, amino acid 6 and / or amino acid 7 are substituted with any amino acid. In some embodiments, amino acid 6 and / or amino acid 7 are independently substituted with asparagine, alanine, serine, or glycine.
[0104] Alternatively or additionally, substitutions can be made at the second meprin site of the ADAM9 prodomain, amino acids 60-62 of SEQ ID NO:2, where amino acid 61 and / or amino acid 62 are substituted. In some embodiments, amino acid 61 and / or amino acid 62 are substituted with any amino acid. In some embodiments, amino acid 61 and / or amino acid 62 are substituted, independently, with asparagine, alanine, serine, or glycine.
[0105] Further alternatively or additionally, substitutions can be made at the third meprin site of the ADAM9 prodomain, amino acids 136-138 of SEQ ID NO:2, where amino acid 137 and / or amino acid 138 are substituted. In some embodiments, amino acid 137 and / or amino acid 138 are substituted with any amino acid. In some embodiments, amino acid 137 and / or amino acid 138 are independently substituted with asparagine, alanine, serine, or glycine.
[0106] Further alternatively or additionally, substitutions can be made at the fourth meprin site of the ADAM9 prodomain, which is amino acids 159-164 of SEQ ID NO:2 (i.e., SEQ ID NO:25), where one, two, three, four or all five of amino acids 160-164 are substituted. In some embodiments, one, two, three, four or all five of amino acids 160-164 are substituted with any amino acid. In some embodiments, one, two, three, four or all five of amino acids 160-164 are independently substituted with asparagine, alanine, serine, or glycine. In some embodiments, at least three of amino acids 160-164 are substituted with any amino acid, which in some embodiments can be independently asparagine, alanine, serine, or glycine. Thus, in some embodiments, amino acids 159-164 of SEQ ID NO:2 (i.e., SEQ ID NO:25) are substituted with KXEXEX, KDXEXE, KDXXXE, KXEXXE, or KXXEXE, where X, in some embodiments, is any amino acid, and in some embodiments, each X is independently selected from the group consisting of asparagine, alanine, serine, or glycine. In some embodiments, at least four of amino acids 160-164 are substituted with any amino acid, which, in some embodiments, may be independently asparagine, alanine, serine, or glycine. Thus, in some embodiments, amino acids 159-164 of SEQ ID NO:2 (i.e., SEQ ID NO:25) are substituted with KDXXXX, KXEXXX, KXXEXX, KXXXEX, or KXXXXE, where X, in some embodiments, is any amino acid, and in some embodiments, each X is independently selected from the group consisting of asparagine, alanine, serine, or glycine. In some embodiments, all five of amino acids 160-164 are substituted with any amino acid, which in some embodiments can be independently asparagine, alanine, serine, or glycine.Thus, in some embodiments, amino acids 159-164 of SEQ ID NO:2 (i.e., SEQ ID NO:25) are substituted with KXXXX, where X, in some embodiments, is any amino acid, and in some embodiments, each X is independently selected from the group consisting of asparagine, alanine, serine, or glycine.
[0107] In addition to and / or instead of any of the meprin modifications described herein above, the meprin recognition site at amino acids 5-7 of SEQ ID NO:2 may, in some embodiments, be modified by a substitution at the amino acid at position 6, the amino acid at position 7, or both. In some embodiments, the substitution at the amino acid at position 6, the amino acid at position 7, or both, is any amino acid. In some embodiments, the substitution at the amino acid at position 6, the amino acid at position 7, or both, is independently selected from the group consisting of asparagine, alanine, serine, or glycine.
[0108] In addition to and / or instead of any of the meprin and / or furin modifications described herein above, one or more of the cysteines involved in disulfide bond formation may be modified. In some embodiments, these cysteines include cysteines 85, 104, and / or 146 of SEQ ID NO:2 in any combination or subcombination. Thus, in some embodiments, the ADAM9 prodomain peptide of the presently disclosed subject matter includes a modification of cysteine 85, a modification of cysteine 104, a modification of cysteine 146, a modification of both cysteines 85 and 104, a modification of both cysteines 104 and 146, or a modification of all of cysteines 85, 104, and 146. In some embodiments, the modifications at these cysteines are any amino acid substitutions, where each of cysteines 85, 104, and 146 are independently substituted with the same or a different amino acid. In some embodiments, cysteines 85, 104, and / or 146 are independently substituted with serine.
[0109] In addition to modifications at positions 6, 7, 24, 26, 27, 61, 62, 85, 104, 137, 138, 146, and 160-164 of SEQ ID NO:3, other modifications of the amino acid sequence of SEQ ID NO:3 may be introduced. By way of example and not limitation, one or more amino acids (in some embodiments, one, two, three, four, five or more amino acids) may be added to the N-terminus and / or C-terminus of the peptide of SEQ ID NO:3. By way of example and not limitation, cysteine residues, alone or in combination with other amino acids, may be added to the N-terminus and / or C-terminus to provide functionality known to be carried by cysteine residues. For example, cysteine residues, alone or in combination with other amino acids, may be added to the N-terminus and / or C-terminus to provide a site for pegylation of the ADAM9 modulating peptide. Exemplary pegylation sites include, but are not limited to, a single cysteine residue at the N-terminus and / or C-terminus, the pentapeptide of SEQ ID NO:26, and / or the pentapeptide of SEQ ID NO:27.
[0110] Thus, in some embodiments, the ADAM9 modulating peptides may be conjugated to a PEG group of about 1-40 kDa by adding a peptide sequence at the N- and / or C-terminus that includes a cysteine to which the PEG group may be attached in some embodiments. The ADAM9 modulating peptides of the presently disclosed subject matter may include peptides that contain additional sequences (e.g., amino acids) at the N- and / or C-terminus that are essential for effective expression of the ADAM9 modulating peptide in E. coli, insect cells, mammalian systems, and the like. In addition, one or more tags may be added that aid in purification of the ADAM9 modulating peptides of the presently disclosed subject matter. Tags may include, but are not limited to, His tags, C-myc tags, Flag tags, HA tags, streptactin tags, disulfide tags, and biotin tags. The sequence between the tag(s) and the prodomain peptide may, in some embodiments, include a protease cleavage site, such as those found for enterokinase, thrombin, and / or Tev proteases. The ADAM9 modulating peptides of the subject matter disclosed herein may include modifications that stabilize the peptide for in vitro use. Such modifications are generally known to those skilled in the art and include, but are not limited to, modifications with fatty acids and pegylation, incorporation of D-amino acids, and substitutions, deletions and / or additions of amino acids.
[0111] Modification and change can be made in the structure of the ADAM9 modulating peptide of the subject matter disclosed herein, and still obtain molecules with ADAM9 modulating properties.For example, specific amino acids can be replaced with other amino acids in sequence without obvious loss of peptide activity.Since it is the interactive ability and properties of a polypeptide that define the activity of biological function of the polypeptide, specific amino acid sequence replacement can be made in the polypeptide sequence, and still obtain polypeptides with ADAM9 modulating properties.
[0112] In making such changes, the hydropathic index of amino acids may be taken into consideration. The importance of the amino acid hydropathic index in conferring interactive biological functions to a polypeptide is generally understood in the art (Kyte & Doolittle, 1982). It is known that certain amino acids may be substituted with other amino acids having similar hydropathic indexes or scores and still result in polypeptides having similar biological functions. Each amino acid is assigned a hydropathic index based on its hydrophobicity and charge characteristics. Their indexes are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamic acid (-3.5); glutamine (-3.5); aspartic acid (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
[0113] It is believed that the relative hydropathic index of amino acids determines the secondary structure of the resulting polypeptide, which in turn defines the interactions of the polypeptide with other molecules, such as enzymes, substrates, receptors, antibodies, antigens, etc. It is known in the art that an amino acid can be substituted for another amino acid having a similar hydropathic index and still obtain a functionally equivalent polypeptide. In such changes, substitutions of amino acids having hydropathic indices within ±2 are preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.
[0114] Substitutions of similar amino acids may be made on the basis of hydrophilicity, particularly when the biologically functional equivalent polypeptides or peptides produced thereby are intended for use in immunological embodiments. U.S. Patent No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a polypeptide, as governed by the hydrophilicity of its adjacent amino acids, correlates with immunogenicity and antigenicity, i.e., a biological property of the polypeptide. As detailed in U.S. Patent No. 4,554,101, the following hydrophilicity values were assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid (+3.0 ± 1); glutamic acid (+3.0 ± 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); proline (-0.5 ± 1); threonine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It will be understood that an amino acid can be substituted for another amino acid having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular an immunologically equivalent, polypeptide. In such changes, substitutions of amino acids whose hydrophilicity values are within ±2 are preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.
[0115] Thus, as outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side chains, such as their hydrophobicity, hydrophilicity, charge, size, etc. Exemplary substitutions taking into account the various aforementioned characteristics are well known to those of skill in the art and include arginine and lysine; glutamic acid and aspartic acid; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine (see Table 3 below). Thus, the subject matter disclosed herein contemplates functional or biological equivalents of the peptides set forth above. [Table 3]
[0116] Biological or functional equivalents of peptides or polypeptides can be prepared by using site-directed mutagenesis according to procedures well known in the art.Thus, amino acid residues can be added to or deleted from the ADAM9 modulating peptides of the subject matter disclosed herein without altering the functionality of the peptides by using standard molecular biology techniques.Specific examples include the human ADAM9 prodomain peptides of the subject matter disclosed herein.
[0117] In some embodiments, the ADAM9 prodomain peptide of the presently disclosed subject matter consists of, consists essentially of, or comprises the amino acid sequence set forth in any of SEQ ID NOs:3-23 and 28-430, 947, or is an ADAM9 prodomain peptide having at least 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology to any one of SEQ ID NOs:3-23 and 28-430, 947. In some embodiments, the ADAM9 prodomain peptide comprises one of SEQ ID NOs:3-23 and 28-430, 947, or is an ADAM9 prodomain peptide having at least 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% homology to one of SEQ ID NOs:3-23 and 28-430, 947, and is pegylated.
[0118] In view of the above, exemplary modified ADAM9 peptides of the presently disclosed subject matter can comprise, consist essentially of, and / or consist of an amino acid sequence set forth in any of SEQ ID NOs:3-23 and 28-430, 947. SEQ ID NO:3 is the general consensus sequence in which positions 6, 7, 24, 26, 27, 61, 62, 85, 104, 137, 138, 146, and 160-164 can be substituted with any amino acid set forth herein. Other non-limiting exemplary modified ADAM9 peptides of the presently disclosed subject matter can comprise, consist essentially of, or consist of an amino acid sequence having the following substitutions relative to SEQ ID NO:3: one, two or all three of cysteines 85, 104 and 146 of SEQ ID NO:3 are substituted with serine and arginine 26 is substituted with alanine; cysteine 146 of SEQ ID NO:3 is substituted with serine, arginine 26 is substituted with alanine, and cysteines 85 and 104 are both substituted with PEG groups of about 1-40 kDa, which in some embodiments improve the in vitro and / or in vivo biological and / or biochemical properties of the modified ADAM9 peptide; · Cysteine 85, cysteine 104 and cysteine 146 are all replaced with serine and arginine 24 is replaced with alanine; · Cysteine 85, cysteine 104 and cysteine 146 are all replaced with serine and arginine 26 is replaced with alanine; · Cysteine 85, cysteine 104 and cysteine 146 are all replaced with serine and arginine 27 is replaced with alanine; · cysteine 85, cysteine 104 and cysteine 146 are all substituted with serine, and one or more arginines at amino acids 24, 26 and / or 27 are substituted with alanine or any amino acid that reduces or eliminates furin or PC convertase cleavage, optionally with a cysteine located C-terminally after amino acid 174; · cysteine 85, cysteine 104 and cysteine 146 are all substituted with serine, and one or more arginines at amino acids 24, 26 and / or 27 are substituted with alanine or any amino acid that reduces or eliminates furin or PC convertase cleavage, optionally with a cysteine located N-terminally before amino acid 1; · cysteine 85 and cysteine 104 are substituted with serine, one or more arginines at amino acids 24, 26 and / or 27 are substituted with alanine, and cysteine 146 is pegylated with a PEG group of about 1-40 kDa; cysteine 85, cysteine 104 and cysteine 146 are all substituted with serine; and one or more arginines at amino acids 24, 26 and / or 27 are optionally substituted with alanines to reduce or eliminate furin cleavage or PC convertase, and one or more of cysteines 85, 104 and 146 are modified to include a maleimide ester, such as, but not limited to, a low molecular weight alkyl ester or an ester with a functional group that renders the cysteine resistant to oxidation or a colorimetric, fluorescent or radioactive labeling group attached.
[0119] In some embodiments, the presently disclosed subject matter provides a pharmaceutical composition comprising an ADAM9 modulating peptide and a physiologically acceptable carrier. In some embodiments, the pharmaceutical composition comprises an ADAM9 modulating peptide consisting of, consisting essentially of, and / or comprising the amino acid sequence set forth in SEQ ID NOs:3-23 and 28-430,947.
[0120] Typically, the compositions of the subject matter disclosed herein are administered parenterally in dosage unit formulations containing standard, well-known, non-toxic, physiologically acceptable carriers, adjuvants, and vehicles, if desired. As used herein, the term parenteral includes intravenous, intramuscular, intraarterial injection, intraperitoneal, topical, or infusion techniques.
[0121] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, are formulated according to known techniques using suitable dispersing or wetting agents and suspending agents.Sterile injectable preparations may also be sterile injectable solutions and / or suspensions in non-toxic parenterally acceptable diluents or solvents, for example as solutions in 1,3-butanediol.
[0122] Exemplary, non-limiting acceptable vehicles and solvents that can be used are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile non-volatile oils are conventionally used as solvents or suspending media. For this purpose, any bland non-volatile oils can be used, including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectable solutions. Preferred carriers include neutral saline solutions buffered with phosphates, lactates, Tris, etc.
[0123] III. METHODS FOR USE OF THE MODIFIED ADAM9 PRODOMAIN PEPTIDES OF THE EMBODIMENTS DISCLOSED HEREIN AND USES OF THESE PEPTIDES The ADAM9 modulating peptides of the subject matter disclosed herein, and compositions comprising or consisting essentially of them, are useful for modulating ADAM9 protein activity in vitro and in vivo. In some embodiments, the subject matter disclosed herein provides a method for modulating ADAM9 activity in vitro, comprising contacting an ADAM9 modulating prodomain peptide with a solution or cells containing an ADAM9 protein under conditions and in an amount sufficient to modulate the activity of the ADAM9 protein (referred to herein as an "effective amount", or in the case of treatment or prophylaxis, as a "therapeutically effective amount").
[0124] In some embodiments, the subject matter disclosed herein provides a method for modulating ADAM9 activity in vivo, the method comprising administering to a subject a therapeutically effective amount of a composition (in some embodiments, a pharmaceutical composition) comprising an ADAM9 modulating prodomain peptide by a route of administration sufficient to modulate ADAM9 activity. In some embodiments, the subject has a disease or disorder characterized, at least in part, by the presence of excessive ADAM9 biological activity (i.e., an undesirable level of ADAM9 biological activity). In some embodiments, the disorder is characterized by one or more of inflammation, allergic response, asthma, angiogenesis, infectious disease, cancer, a predisposition thereto, and / or a symptom or consequence thereof. In some embodiments, the disorder is cancer and the symptom or consequence thereof comprises fibrosis.
[0125] Thus, in some embodiments, the disease or disorder is characterized by one or more of Alzheimer's disease, cancer, inflammation, COPD, neovascular disease, or a predisposition thereto, and / or a symptom or consequence thereof.
[0126] Working Example The following examples provide exemplary embodiments. In light of this disclosure and the general level of skill in the art, it will be apparent to those skilled in the art that the following examples are intended to be illustrative only, and that numerous changes, modifications and alterations may be used without departing from the scope of the subject matter disclosed herein.
[0127] Example 1 Human prodomain peptide of ADAM9 inhibits ADAM9 in vitro His 6ADAM9 prodomain peptides were prepared by cloning a nucleic acid sequence encoding SEQ ID NO:2 with a tag (SEQ ID NO:24) into a plasmid expression vector. Some prodomain peptides were prepared by transformation into BL21DE3 cells followed by expression at 16° C., which produced both soluble prodomain peptides and prodomain peptides in inclusion bodies. Others were prepared by expression at 37° C., which produced inclusion bodies. Soluble prodomain peptides were purified by lysing bacteria in 20 mM Tris pH 8 containing 1 mg / ml Lysozyme (Sigma-Aldrich Corp., St. Louis, MO, USA), Benzonase (Sigma-Aldrich), protease inhibitor cocktail (Gold Biotechnology) and 1× CELLLYTIC® solution (Sigma-Aldrich) with or without 2-5 mM Tris(2-carboxyethyl)phosphine (TCEP; Gold Biotechnology, Inc., St. Louis, MO, USA) for 15-40 min at room temperature. The pellet after centrifugation was treated again with the same buffer and centrifuged once more. For soluble proteins, the first or both supernatants were loaded onto a Ni-NTA column (Fisher Scientific, Philadelphia, PA, USA). After washing, the prodomain was eluted with 2M imidazole, 20 mM Tris pH 9 with or without 5 mM TCEP. The material was then passed through a SUPERDEX® 200 brand column (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) equilibrated with 20 mM Tris pH 8 and 40 mM NaCl. After concentration and endotoxin removal, glycerol was added to 10% and the material was stored at −20° C.
[0128] Inclusion bodies were prepared by breaking open the bacteria as described previously, then centrifuging the material at 3,000 rpm for 30 minutes. The pellet was then resuspended in lysis buffer and shaken at room temperature for 30 minutes, then spun again to pellet the inclusion bodies. The prodomain was purified from the inclusion bodies by solubilization in 8M urea, 20 mM Tris pH 8 with or without 2-4 mM TCEP, then shaken with Ni-NTA beads from Fisher Scientific (Waltham, Massachusetts, USA). The beads were washed with multiple volumes of 8M urea, 20 mM Tris with or without TCEP, then the material was eluted with 6M urea and 20 mM Tris pH 9 with or without 2-4 mM TCEP, and 666 mM imidazole pH 9. The prodomain was refolded from urea and then dialyzed with 20 mM Tris buffer pH 8 to remove residual urea and imidazole. After dialysis, the prodomain was concentrated and incubated with human or mouse ADAM9 at various concentrations in 20 mM Tris pH 8 and 0.001% BRIJ® 35 brand detergent in a black-coated 96-well plate containing 10 μM PEPDAB064 (BioZyme Inc, Apex, NC, USA), a fluorescent energy transfer substrate for ADAM family members. Data was fitted using Prism software to determine IC50 values. The results are shown in Table 4. [Table 4]
[0129] Example 2 Selectivity Profile To determine specificity, wild-type human ADAM9 or SEQ ID NO:10 were incubated with either ADAM10 or ADAM17 (R&D Systems, Minneapolis, MN, USA) and the same substrate buffer mix (greater than 2 μM concentration) as described for ADAM9. They were also incubated with 20 mM Tris / 150 mM NaCl / 10 μM CaCl containing 0.001% BRU® 35 brand detergent. 2 PEPDAB008, BioZyme Inc (Apex, NC, USA) at 15 μM in 100 mM NaCl was used against MMP1, MMP2, MMP9 and MMP14. There was no inhibition of any of the enzymes tested.
[0130] Example 3 Oxidation-induced dimerization and multimerization of the prodomain The wild-type prodomain peptide (SEQ ID NO:2) has three cysteines. All of these cysteines are free and not disulfide bonded as assessed by Ellman's reagent test. Upon incubation at low or higher temperatures, or upon storage at -20°C, the sulfhydryl groups of the protein reacted with each other by oxidation to form disulfide bonds (see Figure 1). The IC50 for inhibition of ADAM9 was typically around 20 nM when ADAM9 was freshly prepared after removing the reducing agent. However, upon dialysis and assay after 1 week, even though it had been frozen, dimer formation occurred, raising the IC50 to 120 nM. Finally, after 1 hour of storage at -20°C, the protein further dimerized and trimerized, eventually precipitating upon thawing. Additionally, after incubation at 37° C. for 0-25 hours, dimer and trimer formation was increased in the wild-type prodomain (SEQ ID NO:2) and SEQ ID NO:9, which has a cysteine to serine substitution at position 146 (see FIG. 2) but still retains cysteines at amino acid positions 85 and 104.
[0131] Example 4 PEGylation of the prodomain allows for proper refolding and improved potency after purification from inclusion bodies SEQ ID NO:10 after elution from Ni-NTA beads in 8M urea, 20mM Tris, and 666mM imidazole pH9 was diluted into 20mM Tris pH9 and left at 4°C overnight. The material was then concentrated and passed through a SUPERDEX® 200 brand size separation column equilibrated with 20mM Tris pH8, 40mM NaCl. Most of the material came off the column near the void volume, indicating that the material was aggregated. The fractions were combined and concentrated. IC50 values were determined by incubation of ADAM9 with various concentrations of the prodomain. The IC50 was greater than 200nM (see Table 4), while the soluble form of SEQ ID NO:10 had an IC50 of 49nM (see Table 4).
[0132] A version of SEQ ID NO:10 with a C-terminal cysteine (SEQ ID NO:20) was solubilized from inclusion bodies and purified with Ni-NTA beads as described in Example 1, then passed through a ZEBA™ brand spin column equilibrated with urea and phosphate buffer. An excess of 20 kDa maleimide PEG (Nanocs Inc, Boston, Massachusetts, USA) was added. After 2 hours, the reaction progress was stopped by adding TCEP to 10 mM. TCEP was incubated with the prodomain for an additional hour, after which the material was refolded and passed through a SUPERDEX® G200 brand column equilibrated with 20 mM Tris pH 8 and 40 mM NaCl. Fractions containing pure PEGylated material were concentrated and passed through a size separation column two more times. The purified fractions were frozen at -20°C after the addition of glycerol. Pegylated SEQ ID NO:20 inhibited ADAM9 with an IC50 of 16±3 nM. In comparison, soluble SEQ ID NO:10 had an IC50 of 49±8 nM, and material refolded from inclusion bodies did not inhibit ADAM9.
[0133] Example 5 Cysteine modification The WT prodomain (SEQ ID NO:2) was passed through a ZEBA™ brand desalting spin column equilibrated with urea and phosphate buffer. 10 μg of the prodomain was reacted with 2 μg of ALEXA FLUOR® 647 brand maleimide ester (Fluoroprobes, Scottsdale, AZ, USA), which can specifically react with sulfhydryl groups, at 4° C. After 3.5 hours, TCEP was added to 20 mM and the reaction was left at 4° C. for an additional hour. The material was then refolded and dialyzed.
[0134] An in vitro assay was used to determine the IC50 for inhibition of ADAM9 (IC50 125±68 nM). Ellman's reagent was used to assess the content of free sulfhydryl groups after the reaction. Approximately 1-3% of the material was unreacted. An SDS gel was run to confirm that labeling had occurred. The results are shown in Figure 3. There was no detectable starting material and the molecular weight of the prodomain had shifted to a larger molecule of approximately 3 kDa, indicating that the protein was correctly labeled.
[0135] Example 6 Cutting experiment There is an upstream site in the prodomain of ADAM9 that is cleaved by furin. We hypothesized that modifications at this site might improve the IC50 or pharmacokinetic properties of inhibition of shedding events by the prodomain of ADAM9. 50 μg of each prodomain was reacted with furin or meprin in a volume of approximately 100 μl in a 1.7 ml Eppendorf tube. For the furin assay, the buffer was 20 mM Tris pH 8 / 150 mM NaCl / 10 mM CaCl 2 Meprin buffer was 20 mM Tris pH 8. Samples were incubated at 37°C and a time course was performed by removing approximately 20-30 μl of the solution and quenching with 10 μl of a 4x solution of loading dye. Samples were run on a 16% Nowex gel and stained with SimplyBlue SafeStain (Thermo Fisher Scientific).
[0136] The results are shown in Figure 4 for furin and in Figures 5-7 for meprin. The results showed that the mutants were resistant to cleavage by furin. SEQ ID NO:12 was the most stable. SEQ ID NO:10, SEQ ID NO:14 and SEQ ID NO:11 were cleaved by furin, but to a much lesser extent than SEQ ID NO:13, which does not have the furin mutation.
[0137] Meprin has been shown to cleave the ADAM10 prodomain, but it is unknown whether it also cleaves the prodomain of ADAM9. We tested improving the selectivity of the prodomain for preventing meprin inhibition while also improving its stability to cleavage. Figure 8 shows that the wild-type prodomain (SEQ ID NO:2) was cleaved by meprin.
[0138] There are at least four possible meprin sites in SEQ ID NO:2. Modifications were made at each site. Site 1 was deleted (see SEQ ID NO:17) so that the prodomain begins after amino acids 1-6 in SEQ ID NO:2. The second site was mutated from PED (amino acids 60-62 of SEQ ID NO:2) to PEA (see SEQ ID NO:14). The third site (amino acids 136-138 of SEQ ID NO:2) was modified from MDD to MDS (see SEQ ID NO:18), and the last site (aa 159-164) was modified from KDEEEE (SEQ ID NO:25) to KDNENE (see SEQ ID NO:19). Based on the truncations in SEQ ID NO:2, it was hypothesized that the first truncation occurred at site 4 (amino acids 159-164). The meprin mutants were more stable than the non-meprin mutants (Figure 5; compare SEQ ID NO:12 with SEQ ID NO:14, SEQ ID NO:18, and SEQ ID NO:19). Furthermore, the pegylated non-meprin mutants, especially pegylated SEQ ID NO:22, which has an N-terminal pegylation site, were more resistant to meprin cleavage (see Figure 7). Unexpectedly, pegylation at the N-terminus protected the prodomain from C-terminal cleavage. Conversely, none of the C-terminally pegylated prodomains protected against C-terminal cleavage. From the cleavage products formed, it can be determined that the C-terminus is the initial cleavage site, likely at the KDEEEE (SEQ ID NO:25) motif. Modification of this site to KDNENE reduced the cleavage rate (see SEQ ID NO:19 in Figure 6) and increased the potency against ADAM9 (see Table 4).
[0139] Example 7 Inhibition of meprin beta by its prodomain Human meprin beta (R&D Systems, Minneapolis, MN, USA) was activated with trypsin according to the manufacturer's instructions, followed by quenching with 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF: Thermo Fisher Scientific). Various concentrations of prodomains were incubated with 15 μM activated meprin beta and fluorescent substrate PEPDAB022 (BioZyme Inc, Apex, NC, USA) in 20 mM Tris pH 8, 0.001% BRIJ® 35 brand detergent in 96-well black coated plates at room temperature. A low concentration of meprin beta and short reaction time were utilized to try to avoid cleavage of the prodomain under these conditions. The reaction rate was linear over time and did not show time-dependent activation. [Table 5]
[0140] Example 8 The human prodomain of ADAM9 inhibited intracellular shedding events in vitro BT474 cells (20,000 cells) were seeded in 96-well plates with growth medium and serum and the prodomain or vehicle control was added at 3 nM to 2.5 μM. The medium was removed and incubated with angiogenesis arrays from RayBiotech (Norcross, GA, USA). Protein levels were quantified by scanning the plates for detection of fluorescent signal. Figure 9 represents data from incubation of 30 and 300 nM of SEQ ID NO:12 (furin mutant) and SEQ ID NO:13 (no furin mutation). In addition, pegylated SEQ ID NO:20 was also tested at 100 nM.
[0141] The results showed that all prodomains were potent inhibitors of VEGFR2 and TGFα shedding (VEGFR2 and TGFα are known substrates of ADAM9), and the furin cleavage-resistant mutants had better efficacy than the non-furin mutants. In addition, the prodomains reduced the levels of other proteins in the medium, such as MMP9, FGF4, MCP-3, MCP-4, and 1309 (see FIG. 9A).
[0142] Example 9 Pharmacological effects of prodomain peptides SEQ ID NO:10 was introduced into a pharmacokinetic study in mice. Briefly, mice (3-6 / group) received a single intraperitoneal (ip) or intranasal dose or vehicle control. In the case of ip injection, blood samples were taken from the two groups by cardiac puncture, or bronchial washes were collected after intranasal administration as post-treatment. Serum or bronchial washes were prepared and stored at -80°C. Proteins in serum or bronchial washes that were increased or decreased by prodomain treatment were quantified. Serum or bronchial wash concentrations of ADAM9 prodomain peptides were also determined indirectly using a bioassay based on the inhibitory ability of the liquids against ADAM9 enzyme activity. 5-50 μl of liquid was incubated with 30 μM substrate PEPDAB064 (BioZyme Inc.) containing protease inhibitors pepstatin, AEBSF, bestatin, and E-64 (trans-epoxysuccinyl-L-leucylamido(4-guanido)butane; CAS number 66701-25-5; Sigma-Aldrich), spiked with 10 μl of ADAM9 prodomain at various concentrations, and the reaction was started by adding ADAM9. The % inhibition of ADAM9 was determined by utilizing known concentrations of ADAM9 prodomain added to serum to generate a standard curve. Then, 5-50 μl of sample was taken and added to 55 μl of the substrate solution, which was diluted 1:6 with the buffer in which the prodomain was dissolved (20 mM Tris buffer pH 8, 40 mM NaCl, and 10% glycerol). The % inhibition was determined relative to fluid collected from a control group of mice injected with a vehicle control.
[0143] After 48 hours, serum prodomain concentrations were approximately 9.4±1.9 μM when administered at 6 mg / kg. To determine whether SEQ ID NO:10 had a biological effect in vivo, the levels of different factors were assessed in serum by comparing vehicle control and treated mice using Raybiotech arrays (Norcross, GA, USA). Table 6 lists some of the factors that were up- or down-regulated by administration of SEQ ID NO:10. [Table 6]
[0144] Example 10 Furin and meprin cleavage-resistant mutants had favorable pharmacokinetic properties PEGylated SEQ ID NOs:21, 22, 23, and non-PEGylated SEQ ID NOs:12 and 14 were injected ip into 2-3 Balb / C mice along with vehicle control (20 mM Tris pH 8, 40 mM NaCl, and 10% glycerol). After 72 hours, blood was collected by cardiac puncture and serum was prepared. Prodomain levels were measured by first generating a standard curve, in which various amounts of each prodomain were incubated in black His-tag coated plates (Fisher Scientific).
[0145] To generate a standard curve, 75 μl of blocking buffer containing protease inhibitor cocktail was spiked with control mouse serum (untreated) and the prodomain. After 30 min, the solution was aspirated and the wells were washed twice with wash buffer and then with assay buffer (20 mM Tris pH 8, 0.001% BRU® 35 brand non-ionic surfactant pH 8). Then, 40-50 μl of assay buffer containing 15 μM PEPDAB064 (BioZyme Inc.) was added to each well and mouse ADAM9 (R&D Systems) was added to initiate the reaction. The % inhibition of ADAM9 was plotted against the prodomain concentration to obtain a standard curve.
[0146] To calculate the levels of prodomains from PK experiments, serum collected at 72 hours was added to 75 μl of blocking buffer as described above and incubated for 30 min. After washing, assay buffer was added along with PEPDAB064 and ADAM9 and the % inhibition was determined again. Serum levels were calculated by fitting the % inhibition to standard curves generated with each prodomain.
[0147] For the PK experiments where serum levels were measured at 72 hours, the results are presented in Figure 10. Pegylated SEQ ID NO:22 was the most stable construct and also the least susceptible to degradation by the combination of meprin and furin. The other pegylated constructs (SEQ ID NO:21 and SEQ ID NO:23) had worse serum levels than SEQ ID NO:12 and pegylated SEQ ID NO:22. Pegylated SEQ ID NO:22 was also more stable than the non-pegylated equivalent SEQ ID NO:12, which is not stable to meprin cleavage. Note that SEQ ID NO:14, which did not have the most stable furin cleavage site, had poorer PK values, even though it has a more stable meprin site.
[0148] Example 11 Acute cigarette smoke model C57BL / 6 strain T mice (8-12 weeks old) were exposed to air or mixed mainstream and sidestream cigarette smoke (CS) for 2 h / day for 6 days / week in Teague TE lOz chambers (Teague Enterprises, Woodland, CA, USA). After 2 weeks, CS-fed mice received 30 μl of either vehicle control (20 mM Tris pH 8, 40 mM NaCl and 10% glycerol) or SEQ ID NO:10 (30 μl at 0.75 mg / kg) intranasally every other day. After an additional 2 weeks of CS exposure, bronchoalveolar lavage fluid (BAL) was obtained and analyzed for elastin degradation (ELISA for desmosine; Cusabio Technology LLC, Houston, TX, USA) as well as pro- and anti-inflammatory mediator arrays (RayBiotech).
[0149] Table 7 presents a list of factors that were decreased in the BAL of CS-exposed mice when comparing control and treatment groups. Factors that were increased include IL1-RA and IL-10, both of which are anti-inflammatory mediators. Elastin degradation, as measured by desmosine levels, is extremely high in CS-exposed mice. BAL desmosine levels are shown in FIG. 11. Administration of SEQ ID NO:10 completely prevented elastin degradation. SEQ ID NO:10 levels were determined 30 minutes after administration using the bioassay previously described in Example 8. BAL levels were approximately 10 μM when administered at 0.75 mg / kg. [Table 7]
[0150] Example 12 Acute liver injury and fibrosis models Eighteen male 8-week-old BALB / c mice were randomized into test groups based on body weight. 4 Treatment with the solution was initiated in all mice and continued for a period of two weeks. Therapeutic treatment consisted of CCl 4Compound administration and CCl4 solution were separated by at least 4 hours during this 2-week prophylactic dosing study, as outlined in Table 8. [Table 8] BIW: twice a week; EOD: every other day
[0151] At the end of the study, approximately 400 μl of whole blood was collected into serum separator tubes for ALT, AST, ALP and bilirubin analysis. Following the final blood collection, the liver of each mouse was isolated, weighed and dissected into four sections as follows: a central section of the left lobe was formalin fixed (FFPE) for histological analysis, and three smaller separate sections, one from the remaining left lobe and two from the right lobe (approximately 50-100 mg each), were snap frozen and stored at -0°C.
[0152] Histological Analysis: Liver fibrosis scoring of H&E / PSR stained liver sections from FFPE livers harvested at termination was provided by a Board Certified Veterinary Pathologist (DVM). Scoring included fibrosis and other relevant observations such as necrosis and inflammation.
[0153] Figure 11 shows the results of the study. Compared to the control group, liver weight was reduced, indicating a beneficial effect of compound treatment. AST and ALT levels as well as bilirubin levels were also reduced in the treatment group. Finally, there was also a reduction in liver fibrosis scores. Liver samples were collected, lysates were made, and enzyme levels of MMP and ADAM family members were quantified using Proteolytic Activity Matrix Analysis (PrAMA; Miller et al., 2011) with five different fluorescent substrates. In this analysis, MMP9 and ADAM8 levels were reduced in the treatment group, while MMP13 levels were increased (see Figure 13).
[0154] Example 13 In vitro testing: Tumor xenograft models To determine whether the ADAM9 prodomain has therapeutic potential for tumor growth inhibition in vivo, efficacy studies are performed utilizing an induced xenograft tumor model in athymic mice. Briefly, 1×10 cells were cultured in 1×10 7 The tumors are implanted sc into the flanks of 6-week-old female athymic mice. The tumor size in two dimensions is measured with a caliper and the volume is calculated. When the tumor size is approximately 200 mm 3 Treatment begins when the ADAM9 prodomain peptide is reached. Vehicle control and two doses of ADAM9 prodomain peptide alone are given as determined from pharmacokinetic data. Each treatment group (n=6-12 / group) is monitored for up to 7-8 weeks. Body weight and tumors are measured twice weekly to determine tumor growth and shrinkage. Animals are euthanized at the end of the experiment and liver, heart, visceral fat, kidneys and brain are retained and examined for tissue damage and toxicity.
[0155] The ADAM9 prodomain peptide is used in combination with other cancer drugs in xenograft tumor models at appropriate doses. The cancer drugs are administered alone or in combination with the ADAM9 prodomain peptide, and the experiments are carried out as described above.
[0156] Example 14 Inhibition of neovascularization by prodomain peptides Choroidal neovascularization (CNV) is a leading cause of severe vision loss, primarily in patients with age-related macular degeneration. A murine model of CNV is used to test the ability of an ADAM9 prodomain peptide to inhibit neovascularization. Thirteen male adult C57BL / 6J mice (13 mice / group, 2 groups) are anesthetized by intraperitoneal injection of 0.3 ml of ketamine hydrochloride diluted 1:10 in sterile water. Pupils are dilated with 1% tropicamide, and three burns of krypton laser photocoagulation (50 μm spot size; 0.05 seconds; 350-400 mW) are performed on each retina utilizing a slit lamp delivery system and a cover glass as a contact lens to detect retinal dissection. The generation of bubbles at the time of the laser indicates the collapse of Bruch's membrane.
[0157] Cauteries that produced bubbles are included in the study. Cauteries are performed at the 9, 12, and 3 o'clock positions of the posterior pole of the retina so that each cautery can be identified at necropsy and compared for fluorescein angiographic and histopathological features. Prodomain peptide or vehicle control (20 mM Tris pH 8, 10% glycerol) is given ip for 1-4 weeks, during which fluorescein angiography is performed in some mice by taking serial fundus photographs with a TRC-50FT camera (Topcon, Paramus, NJ, USA) after ip injection of 0.3 ml of 1% sodium fluorescein (Alcon, Fort Worth, TX, USA). At various times after laser treatment, mice are sacrificed and their eyes are enucleated and fixed for 24 hours at 4°C in 2% paraformaldehyde / 2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) or in the same buffer containing only 4% paraformaldehyde. Cauteries are randomly selected over the treatment period to obtain an estimate of the incidence of CNV at various times after laser treatment. Lesions are examined by light microscopy and some lesions are also analyzed by transmission electron microscopy.
[0158] Example 15 Inhibition of wound healing by prodomain peptides C57 / B16 (8-10 weeks old; 8 animals / group; 2 groups) mice are anesthetized with a single ip injection of ketamine / xylazine. The back is shaved and the skin wiped with 70% ethanol. Two full-thickness incision wounds (4 mm diameter) are made on the back of each animal by excising the skin and cutaneous sarcolemma muscle as previously described. The wounds are left to dry and form scabs. Animals are administered vehicle control (20 mM Tris pH 8, 10% glycerol) or prodomain by IP injection or topical application every 1-3 days for 2 weeks. Mice are sacrificed at different time points after wounding and all wounds, including the epithelial periphery, are isolated. Wounds are bisected caudally and cranially and tissues are embedded in OCTCompound (Tissue Tek, Vogel, Giessen, Germany) and used for immunohistochemistry. Histological analysis is performed on serial sections from the central part of the wound. Frozen sections (5 μm) of the wounds are stained with hematoxylin and eosin (H&E; Shandon, Franklin, Germany), recorded and measured using a Leica microscope (DMLB, Wetzlar, Germany).
[0159] Example 16 Treatment of Alzheimer's Disease with Prodomain Peptides 8-week-old PDAPP, APP |V7171|or Tg2576 mice (10 / group, 2 groups) are given vehicle control or prodomain intranasally or intracerebrally every 1-7 days over the course of 3-7 months. Brains are dissected and immunohistochemistry and quantitative plaque analysis are performed. Briefly, one hemisphere is fixed in 4% paraformaldehyde in PBS for 24 hours and the frontal quadrant is embedded in paraffin. Amyloid plaques are identified with antibody 6F / 3D, which detects Aβ40 and 42. The occipital paraformaldehyde-fixed quadrant is used for quantification of amyloid plaque burden in the subiculum using thioflavin S staining of vibratome-cut sections (40 μm thick). Fluorescence images were acquired with an inverted microscope (Leica DMR; Leica Microsystems, Bensheim, Germany) equipped with a 3CCD digital camera (Sony DXC-9100P; Sony Corp., Cologne, Germany) and analyzed with dedicated software (Leica QWin system). The total surface area of amyloid deposits was measured and expressed as a percentage of the total surface of the subiculum.
[0160] For electrophysiological testing, hippocampal slices are prepared from anesthetized mice using a vibratome. The slices are then incubated with warmed oxygenated artificial spinal fluid in an immersion chamber. The Schaffer collateral pathway is then stimulated using bipolar tungsten microelectrodes. Mice are also subjected to the Morris water maze. Nine to ten mice per group are trained in the maze using the Morris water maze task, which includes a submerged platform. Four trials per day over four days were performed with a maximum duration of 90 seconds, with a 90-second break between each.
[0161] Mice are first placed on the platform for 30 seconds. On the fifth day, a 60 second test without the platform is performed. The time to reach the expected platform location is measured and expressed as latency. In addition, the number of annulus crossings is calculated.
[0162] Reference materials All references listed below and all references cited in this disclosure, including, but not limited to, all patents, patent applications and publications thereof, scientific journal literature, and database entries (e.g., the GENBANK® Biosequencing database entries and all annotations available therein), are incorporated by reference in their entirety herein to the extent that they supplement, explain, provide background to, or teach the methodologies, techniques and / or compositions used herein.
[0163] Banerjee et al. (2011) American Journal of Physiology-Gastrointestinal and Liver Physiology 300:G273-282. Bergin et al. (2008) Journal of Biological Chemistry 283:31736-31744. Deuss et al. (2008) Current Alzheimer Research 5: 187-201. Edwards et al. (2008) Molecular Aspects of Medicine 29(5):258-289. Guaiquil et al. (2009) Molecular and Cellular Biology 29(10):2694-2703. Jefferson et al. (2013) Cellular and Molecular Life Sciences 70:309-333. Kyte & Doolittle (1982) Journal of Molecular Biology 157:105-132. Ludwig et al. (2005) Combinatorial Chemistry & High Throughput Screening 8(2):161-171. Maretzky et al. (2017) The Biochemical Journal 474(9): 1467-1479. Mauch eta. (2014) The Journal of Investigative Dermatology 130:2120-2130. Miller et al. (2011) Integr Biol (Camb) 3:422-438. Moss et al. (2008) Nature Clinical Practice Rheumatology 4(6):300-309. Moss et al. (2011) Journal of Biological Chemistry 286(47):40443-40451. Pruessmeyer & Ludwig (2009) Seminars in Cell & Developmental Biology 20(2): 164-174. Roychaudhuri et al. (2014) Journal of Immunology 193:2469-2482. Sahin et al. (2004) The Journal of Cell Biology 164(5):769-779. Schutte et al. (2014) Proceedings of the National Academy of Sciences of the United States of America 111:12396-12401. Vazeille et al. (2011) Role of meprins to protect ileal mucosa of Crohn's disease patients from colonization by adherent-invasive E. coli, PLoS One 6:e21199. Wang et al. (2018) A Disintegrin and A Metalloproteinase-9 (ADAM9): A Novel Proteinase Culprit with Multifarious Contributions to COPD. American Journal of Respiratory and Critical Care Medicine. Jun 4. doi: 10.1164 / rccm.201711-2300OC. [Epub ahead of print] Wong et al. (2015) Journal of Biological Chemistry 290(19): 12135-12146. Wong et al. (2016) Scientific Reports 6:35598. Zhou et al. (2006) Cancer Cell 10(l):39-50.
[0164] It will be understood that various details of the subject matter disclosed herein can be changed without departing from the scope of the subject matter disclosed herein. Further, the foregoing description is intended to be illustrative and not limiting.
Claims
1. 1. A peptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in SEQ ID NO:3, wherein said peptide comprises one or more amino acid substitutions and / or modifications at amino acid positions selected from the group consisting of amino acid 6, 7, 24, 26, 27, 61, 62, 85, 104, 137, 138, 146, 160, 161, 162, 163, and 164, relative to the amino acid sequence set forth in SEQ ID NO:2, such that said peptide is less inhibitory to meprin, less sensitive to furin cleavage, less susceptible to oxidation and / or disulfide bond formation, or any combination thereof, relative to a peptide lacking said one or more amino acid substitutions and / or modifications.
2. The peptide comprises, consists essentially of, or consists of an amino acid sequence that is at least 90% identical to SEQ ID NO:2, and further comprises, relative to SEQ ID NO:2, the amino acid sequence: (i) substitution of arginine 24 with another amino acid, optionally alanine, serine, glycine, or lysine; (ii) substitution of arginine 26 with another amino acid, optionally alanine, serine, glycine, or lysine; (iii) substitution of arginine 27 with another amino acid, optionally alanine, serine, glycine, or lysine; (iv) substitution of cysteine 85 with another amino acid, optionally serine, alanine, or glycine; (v) substitution of cysteine 104 with another amino acid, optionally serine, alanine, or glycine; (vi) substitution of cysteine 146 with another amino acid, optionally serine, alanine, or glycine; and (vii) one, two or all three chemical modifications of cysteines 85, 104, and 146; or any combination thereof, 2. The peptide of claim 1, comprising one or more amino acid substitutions and / or modifications selected from the group consisting of:
3. Compared to SEQ ID NO:2, the amino acid sequence: (i) having a substitution at one or both of amino acids 6 and 7, each substitution independently being any amino acid other than the amino acid present at the corresponding position in SEQ ID NO:2, optionally with each substitution independently being selected from the group consisting of asparagine, alanine, serine, and glycine; or (ii) having a substitution at one, two, or all three of amino acids 24, 26, and 27, each substitution independently being any amino acid other than the amino acid present at the corresponding position in SEQ ID NO:2, optionally with each substitution independently being selected from the group consisting of alanine, serine, glycine, and lysine; or (iii) having a substitution at one or both of amino acids 61 and 62, each substitution independently being any amino acid other than the amino acid present at the corresponding position in SEQ ID NO:2, optionally with each substitution independently being selected from the group consisting of asparagine, alanine, serine, and glycine; or (iv) having a substitution at one or both of amino acids 137 and 138, each substitution independently being any amino acid other than the amino acid present at the corresponding position in SEQ ID NO:2, optionally with each substitution independently being selected from the group consisting of asparagine, alanine, serine, and glycine; or (v) having one, two, three, four, or all five substitutions at amino acids 160-164, each substitution independently being any amino acid other than the amino acid present at the corresponding position in SEQ ID NO:2, optionally with each substitution independently being selected from the group consisting of asparagine, alanine, serine, and glycine; or (vi) having a substitution at one, two, or all three of amino acids 85, 104, and 146, wherein each substitution is independently any amino acid other than cysteine, and optionally each substitution is independently selected from the group consisting of serine, alanine, and glycine; Or any combination of the above.
4. Compared to SEQ ID NO:2, the amino acid sequence: (vii) a substitution at amino acid 24 and a substitution at amino acid 26, wherein the first substitution and the second substitution are optionally independently selected from the group consisting of alanine, serine, glycine, and lysine; or (viii) a substitution at amino acid 24 and a substitution at amino acid 27, wherein the first substitution and the second substitution are optionally independently selected from the group consisting of alanine, serine, glycine, and lysine, and further optionally wherein amino acids 24 and 27 are both lysines or both glycines, or one of amino acids 24 and 27 is glycine and the other is lysine; or (ix) a substitution at amino acid 26 and a substitution at amino acid 27, wherein the first substitution and the second substitution are optionally independently selected from the group consisting of alanine, serine, glycine, and lysine; or (x) a substitution at amino acid 24, a substitution at amino acid 26, and a substitution at amino acid 27, all of which are optionally independently selected from the group consisting of alanine, serine, glycine, and lysine; or (xi) a substitution at amino acid 85 and a substitution at amino acid 104, which substitutions are optionally independently selected from the group consisting of serine, alanine, and glycine, and further optionally, each of amino acids 85 and 104 is a serine; or (xii) a substitution at amino acid 85 and a substitution at amino acid 146, which substitutions are optionally independently selected from the group consisting of serine, alanine, and glycine, and further optionally, each of amino acids 85 and 146 is a serine; or (xiii) a substitution at amino acid 104 and a substitution at amino acid 146, which substitutions are optionally independently selected from the group consisting of serine, alanine, and glycine, and further optionally, each of amino acids 104 and 146 is a serine; or (xiv) having a substitution at each of amino acids 85, 104, and 146, which substitution is optionally independently selected from the group consisting of serine, alanine, and glycine, and further optionally, each of amino acids 85, 104, and 146 is serine; or (xv) a substitution at amino acid 85 and a chemical modification at amino acid 104, amino acid 146, or both, wherein the substitution is optionally selected from the group consisting of serine, alanine, and glycine, and further optionally wherein the substitution is serine; or (xvi) a substitution at amino acid 104 and a chemical modification at amino acid 85, amino acid 146, or both, wherein the substitution is optionally selected from the group consisting of serine, alanine, and glycine, and further optionally, the substitution is serine; or (xvii) a substitution at amino acid 146 and a chemical modification at amino acid 85, amino acid 146, or both, wherein the substitution is optionally selected from the group consisting of serine, alanine, and glycine, and further optionally, the substitution is serine; or (xviii) having a substitution at one, two, or all three of amino acids 161, 163, and 164, each substitution optionally being selected from the group consisting of asparagine, glycine, alanine, and serine; or (xix) having a substitution at one, two, or all three of amino acids 162-164, each substitution optionally being selected from the group consisting of asparagine, glycine, alanine, and serine; Or any combination thereof.
5. Compared to SEQ ID NO:2, the amino acid sequence: (xx) a serine at amino acid 85 and a serine at amino acid 104; (xxi) an alanine at amino acid 26 and a serine at amino acid 146; (xxii) an alanine at amino acid 26 and a serine at amino acids 85, 104, and 146; (xxiii) an alanine at amino acid 24 and a serine at amino acids 85, 104, and 146; (xxiv) an alanine at amino acid 27 and a serine at amino acids 85, 104, and 146; (xxv) serine at amino acids 85, 104, and 146; (xxvi) an alanine at amino acid 26; and a serine at amino acids 85, 104, and 146; and an alanine at amino acid 62; (xxvii) a glycine at amino acid 27 and a serine at amino acids 85, 104, and 146; (xxviii) a serine at amino acid 27 and a serine at amino acids 85, 104, and 146; (xxix) an alanine at amino acid 27; a serine at amino acids 85, 104, and 146; and a deletion of amino acids 1 to 6 of SEQ ID NO:3; (xxx) an alanine at amino acid 27 and a serine at amino acids 85, 104, and 146 and a serine at amino acid 138; (xxxi) an alanine at amino acid 27, a serine at amino acids 85, 104, and 146, and an asparagine at amino acids 161 and 163; (xxxii) the addition of an alanine at amino acid 26 and a serine at amino acids 85, 104, and 146, and the GSGSC (SEQ ID NO:27) pentapeptide C-terminal to amino acid 174 of SEQ ID NO:3; (xxxiii) an alanine at amino acid 27 and a serine at amino acids 85 and 104; (xxxiv) an alanine at amino acid 27 and serine at amino acids 85, 104, and 146, and the addition of the GSCGS (SEQ ID NO:26) pentapeptide N-terminal to amino acid 1 of SEQ ID NO:3; and (xxxv) an alanine at amino acid 27 and serine at amino acids 85, 104, and 146, and the addition of the GSGSC (SEQ ID NO:27) pentapeptide C-terminal to amino acid 174 of SEQ ID NO:3; The peptide of claim 3, having the formula:
6. 2. The peptide of any one of the preceding claims, wherein one, two, or all three of cysteines 85, 104, and 146 are chemically modified at their sulfhydryl groups, optionally wherein said sulfhydryl group(s) are chemically modified by addition of a maleimide ester, an α-halocarbonyl, a thiosulfonate, or any combination thereof.
7. 2. The peptide of any one of the preceding claims, wherein the amino acid sequence comprises, consists essentially of, or consists of one or more substitutions of arginines 24, 26, and / or 27 with amino acids other than arginine, one or more substitutions of cysteines 85, 104, and 146 with amino acids other than cysteine, optionally serine, or any combination thereof.
8. 2. The peptide of any one of the preceding claims, further comprising a pegylated cysteine attached to the N-terminus, the C-terminus, or both, optionally wherein one or both of the pegylated cysteines comprises a PEG group having a molecular weight of from about 1 kilodalton (kDa) to about 40 kDa.
9. 2. The peptide of any one of the preceding claims, wherein the amino acid sequence comprises, consists essentially of, or consists of at least one substitution of arginine 24, arginine 26, and arginine 27 with an amino acid other than arginine, and substitution of cysteines 85, 104, and 146 with serine.
10. 2. The peptide of any one of the preceding claims, wherein the amino acid at position 146 is a cysteine and further wherein cysteine 146 is pegylated, optionally wherein cysteine 146 comprises a PEG group having a molecular weight of from about 1 kDa to about 40 kDa.
11. 2. The peptide of claim 1, wherein one or more of cysteines 85, 104, and 146 comprise a chemical modification with a maleimide ester.
12. 12. The peptide of claim 11, further comprising modifying arginine 24, arginine 26, and / or arginine 27 to increase the resistance of the peptide to furin cleavage.
13. 2. A peptide according to any one of the preceding claims, wherein one or more of cysteines 85, 104 and 146 comprise a chemical modification obtained by reacting said one or more cysteines with a disulfide.
14. 14. The peptide of claim 13, further comprising modifying arginine 24, arginine 26, and / or arginine 27 to increase the resistance of the peptide to furin cleavage.
15. 2. The peptide according to any one of the preceding claims, wherein said peptide comprises, consists essentially of or consists of an amino acid sequence having at least 87% identity to any one of SEQ ID NOs: 3-23 and 28-430,947, optionally wherein said identity is at least 95%.
16. 16. The peptide of claim 15, wherein the peptide comprises, consists essentially of, or consists of an amino acid sequence having 100% percent identity over its entire length to any one of SEQ ID NOs: 3-23 and 28-430,947.
17. 2. The peptide of any one of the preceding claims, wherein the peptide further comprises one or more additional modifications selected from the group consisting of conservative amino acid substitutions, unnatural amino acid substitutions, D- or D,L-racemic mixture isomeric amino acid substitutions, amino acid chemical substitutions, carboxy- and / or amino-terminal modifications, glycosylation, and conjugation to biocompatible molecules such as, but not limited to, fatty acids and the peptide of interest.
18. 2. The peptide of any one of the preceding claims, wherein the peptide further comprises at least one modification of cysteines 85, 104, and / or 146, the modification comprising attachment of a maleimide ester derivative comprising at least one moiety selected from the group consisting of a PEG group, a fluorescent moiety, an alkyl moiety, a colorimetric moiety, a bifunctional moiety, a radiometric moiety, a glycosyl moiety, a fatty acid moiety, a toxin, a therapeutic agent, optionally a chemotherapeutic agent, a linker, a peptide, or any combination thereof.
19. A composition comprising a peptide according to any one of claims 1 to 18, which is a pharmaceutical composition formulated for administration to a subject or formulated for administration to a human.
20. A fusion protein comprising the peptide according to any one of claims 1 to 18.
21. The fusion protein of claim 20, wherein the peptide is conjugated to an agent selected from the group consisting of a therapeutic moiety, a diagnostic moiety, a detectable moiety, or any combination thereof, and optionally the peptide is conjugated to the agent via a linker molecule or via a peptide bond.
22. 22. The fusion protein of claim 21, wherein the therapeutic molecule is selected from the group consisting of a therapeutic antibody, an Fc fragment, a receptor, a toxin, a chemotherapeutic molecule, or any combination thereof.
23. A polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any of SEQ ID NOs: 3-23 and 28-430,947.
24. 24. The polypeptide of claim 23, further comprising a tag, optionally a His tag, that can be used for purification and / or isolation of the polypeptide from an expression system.
25. 25. The polypeptide of claim 24, further comprising a recognition site for a protease between the tag and an amino acid of the polypeptide that can be used to release the tag from the polypeptide by proteolytic cleavage.
26. 1. A polypeptide comprising an amino acid sequence as set forth in any one of SEQ ID NOs: 3-23 and 28-430,947, further comprising the addition of one or more amino acids to the N-terminus of said polypeptide, the addition of one or more amino acids to the C-terminus of said polypeptide, or the addition of one or more amino acids to both the N-terminus and C-terminus of said polypeptide, wherein said one or more amino acids comprises at least one cysteine residue that provides functionality for conjugating a moiety of interest to said polypeptide.
27. 27. The polypeptide of claim 26, wherein the one or more amino acids added to the N-terminus of the polypeptide comprise, consist essentially of, or consist of SEQ ID NO: 26 and / or the one or more amino acids added to the C-terminus of the polypeptide comprise, consist essentially of, or consist of SEQ ID NO:
27.
28. 28. The polypeptide of claim 26 or 27, further comprising a PEG group conjugated to a cysteine present in the one or more amino acids added to the N-terminus and / or C-terminus of the polypeptide, wherein the PEG group enhances proper folding of the polypeptide and / or stabilizes the polypeptide against meprin cleavage compared to the polypeptide lacking a PEG group.
29. A method for modulating ADAM9 biological activity in vitro, comprising contacting a solution or cells containing ADAM9 protein with a peptide described in any one of claims 1 to 18 or a composition described in claim 19 in an amount sufficient to inhibit the activity of the ADAM9 protein.
30. A method for inhibiting ADAM9 biological activity in a subject, comprising administering to the subject a peptide described in any one of claims 1 to 18 or a composition described in claim 19 in an amount and by a route sufficient to contact an ADAM9 polypeptide present in the subject, thereby modulating ADAM9 biological activity in the subject's body.
31. 1. A method for inhibiting ADAM9 biological activity in vivo, comprising administering to a subject a polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence set forth in any one of SEQ ID NOs: 3-23 and 28-430,947 in an amount and by a route sufficient to inhibit ADAM9 biological activity in vivo, wherein optionally the polypeptide is pegylated.
32. A method for inhibiting ADAM9 biological activity associated with a disease or disorder in a subject, comprising contacting an ADAM9 protein present in the subject with an effective amount of a peptide described in any one of claims 1 to 18 or a composition described in claim 19, wherein the disease or disorder is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, wounds, and unwanted angiogenesis, or the subject has a predisposition thereto.
33. 33. The method of claim 32, wherein the disease or disorder comprises lung injury, optionally lung injury caused by exposure to tobacco smoke, and the effective amount is sufficient to reduce elastin degradation, inflammation, matrix metalloprotein bioactivity, or any combination thereof, in one or both of the subject's lungs.
34. The method of claim 32, wherein the disease or disorder includes lung injury, and optionally liver injury associated with liver fibrosis, and the effective amount is sufficient to reduce the biological activity of an MMP9 gene product, an ADAM8 gene product, or any combination thereof in the liver of the subject.
35. 33. The method of claim 32, wherein the disease or disorder results at least in part from excessive cell proliferation associated with ADAM9 biological activity.
36. The method of any one of claims 30 to 35, wherein the subject has a disease or disorder characterized at least in part by undesirably high ADAM9 biological activity or ADAM9 protein expression.
37. The method of claims 30-35, wherein the subject has a disease or disorder characterized at least in part by decreased ADAM10 activity.
38. A method for reducing inflammation, comprising administering to a subject an effective amount of a peptide according to any one of claims 1 to 18 or a composition according to claim 19.
39. A method for inhibiting cell infiltration associated with undesirable ADAM9 biological activity in a subject, comprising administering to the subject an effective amount of a peptide described in any one of claims 1 to 18 or a composition described in claim 19.
40. 1. A method for inhibiting release of an ADAM9 substrate in vivo, comprising administering to a subject in need thereof a peptide comprising, consisting essentially of, or comprising an amino acid sequence set forth in any one of SEQ ID NOs: 3-23 and 28-430,947, wherein optionally the peptide is pegylated.
41. 41. The method of any one of claims 30 to 40, wherein the peptide of any one of claims 1 to 18 or the composition of claim 19 is formulated for administration via a route selected from the group consisting of inhalation, oral administration, intraadipose administration, intra-arterial administration, intra-articular administration, intracranial administration, intradermal administration, intralesional administration, intramuscular administration, intranasal administration, intraocular administration, intrapericardial administration, intraperitoneal administration, intrapleural administration, intraprostatic administration, intrarectal administration, intrathecal administration, intratracheal administration, intratumoral administration, intraumbilical administration, intravaginal administration, intravenous administration, intravesical administration, intravitreal administration, subconjunctival administration, subcutaneous administration, sublingual administration, topical administration, transbuccal administration, oropharyngeal aspiration, and transdermal administration.
42. The method according to claim 41, wherein the peptide according to any one of claims 1 to 18 or the composition according to claim 19 is delivered in a lipid composition, optionally in a liposome or ethosome; in a cream; via a catheter; by lavage; via infusion, optionally continuous infusion; via inhalation; via injection; via topical delivery; via localized perfusion; by directly bathing the target cells; or any combination thereof.
43. 1. A method for attaching a peptide consisting of, consisting essentially of, or comprising the amino acid sequence set forth in any of SEQ ID NOs: 3-23 and 28-430,947 to an antibody, antibody fragment, or other protein, comprising conjugating the peptide to the antibody, antibody fragment, or other protein, optionally via a linker, and further optionally via a peptide linker.
44. Use of an antibody, antibody fragment, polypeptide, protein, specific antibody, monoclonal antibody, peptide, inhibitory nucleic acid, and / or low molecular weight inhibitor of ADAM9 biological activity for preventing the onset and / or reducing the severity of at least one symptom of a disorder associated with undesirable ADAM9 biological activity in a subject in need thereof, wherein the disorder associated with undesirable ADAM9 biological activity is optionally selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, and undesirable angiogenesis.
45. 45. The use of claim 44, wherein the subject is a human.
46. 46. The use according to claim 44 or 45, wherein the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of COPD and fibrosis, and optionally the fibrosis is liver fibrosis.
47. A peptide comprising, consisting essentially of, or consisting of any of SEQ ID NOs: 3-23 and 28-430,947, wherein at least one meprin cleavage site present therein is modified to render said peptide less inhibitory to meprin.
48. The at least one meprin cleavage site is selected from the group consisting of amino acids 5-7 of SEQ ID NO:3, amino acids 60-62 of SEQ ID NO:3, amino acids 136-138 of SEQ ID NO:3, and amino acids 140-142 of SEQ ID NO:
3.
48. The peptide of claim 47, wherein said at least one meprin cleavage site is selected from the group consisting of amino acids 159-164 of SEQ ID NO:3, and further wherein said at least one meprin cleavage site present therein is modified to comprise an amino acid sequence selected from the group consisting of FXX, PXX, MXX, FXQ, FQX, PXD, PEX, MXD, MDX, KXEXEX, KDXEXE, KDXXXE, KXEXXXE, KXXEXE, KDXXXX, KXEXXX, KXXEXXX, KXXXEX, KXXXXE, KXXXXX, or any combination thereof, wherein each X is independently any amino acid sequence, and further optionally each X is independently selected from the group consisting of asparagine, glycine, alanine, and serine.
49. A polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any one of SEQ ID NOs: 3-23 and 28-430,947, wherein a cysteine corresponding to an amino acid residue in SEQ ID NO: 3 selected from the group consisting of cysteines 85, 104, and 146, or any combination thereof, is conjugated to one or more moieties which improve the inhibitory potency, solubility, and / or pharmacokinetic properties of said polypeptide compared to said polypeptide lacking said moieties, and / or is conjugated to one or more chromophores, fluorophores, and / or radionuclides.
50. 1. A polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence as set forth in one of SEQ ID NOs: 3-23 and 28-430,947 for use in treating a subject having a disorder associated with undesired ADAM9 biological activity, optionally wherein said disorder associated with undesired ADAM9 biological activity is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, wounds, and undesired angiogenesis, and optionally wherein said polypeptide is pegylated at one or more of said amino acids of SEQ ID NOs: 3-23 and 28-430,947.
51. 51. The polypeptide of claim 50, wherein the polypeptide is pegylated.
52. 52. The polypeptide of claim 50 or 51, wherein the subject is a human.
53. Use of an inhibitor of ADAM9 biological activity to treat a subject having a disorder associated with undesired ADAM9 biological activity, wherein the inhibitor of ADAM9 biological activity is selected from the group consisting of an antibody or a fragment thereof, optionally wherein the antibody is a monoclonal antibody, a protein, a peptide, an inhibitory nucleic acid, and / or a low molecular weight substance, and optionally wherein the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, wounds, and undesired angiogenesis.
54. 54. The use of claim 53, wherein the subject is a human.
55. 1. A polypeptide comprising, consisting essentially of, or consisting of an amino acid sequence as set forth in one of SEQ ID NOs: 3-23 and 28-430,947 for use in preventing the onset of and / or reducing the severity of at least one symptom of a disorder associated with undesired ADAM9 biological activity, optionally wherein said disorder associated with undesired ADAM9 biological activity is selected from the group consisting of cancer, inflammation, COPD, fibrosis, Alzheimer's disease, wounds, and undesired angiogenesis, in a subject in need thereof, and optionally wherein said subject has a predisposition to developing at least one symptom.
56. 56. The polypeptide of claim 55, wherein the polypeptide is pegylated.
57. 57. The polypeptide of claim 55 or 56, wherein the subject is a human.
58. 58. A polypeptide according to any one of claims 55 to 57, wherein the disorder associated with undesired ADAM9 biological activity is selected from the group consisting of COPD and fibrosis, and optionally the fibrosis is liver fibrosis.
